Curriculum vitae for John Vissing

Personal data

Danish citizen. Born in Copenhagen, Denmark on the 28th of June, 1960
Private address: Helsinkigade 20, 11-2, 2150 Nordhavn, Denmark
Phone: +45-40603283 (cell); +45-35452562 (work)
E-mail: john.vissing@regionh.dk

Pregraduate activities

1976:	Graduation from Sct. George's English School of Rome (O levels).
1979:	Graduation from Marie Kruse's Gymnasium (math-science). Grade average; 9.6.
1979:	Matriculation at Medical school, University of Copenhagen.
1985-86:	Scholarship (from Carlsberg Foundation) at Department of Medical Physiology, Panum Institute, University of Copenhagen.
1986:	Graduation from Medical school, University of Copenhagen. Grade average 10.5 (3rd highest of 168 students).

Postgraduate positions

- 1986-89: Research fellow at the Department of Medical Physiology, University of Copenhagen and Department of internal medicine, Southwestern Medical Center, University of Texas, Dallas, USA
- 1989-91: 20 months internal medicine and 6 months urology internship
- 1991-now: Positions in neurology (+ psychiatry, neurosurgery and neurophysiology, 6 months each)
- Consultant neurologist at Rigshospitalet, Copenhagen, and Director of the Neuromuscular Clinic, since 2000
- Lecturer and associate professor of neurology at the University of Copenhagen since 2001
- Professor of Neuromuscular diseases at University of Copenhagen since 2007

Administrative activities

On the board of;

- The Clinical Genetic Council at Rigshospitalet 2000-2004
- The Committee for Clinical Studies (Klinikudvalget) 2001-2008
- The Research Committee of the Neuroscience Center at Rigshospitalet 2000- 2010
- The central Research Committee of Rigshospitalet (Forskningsudvalgets formandskab) from 2006-2014

- Chairman of of the stipend committee under the Central Research Committee at Rigshospitalet 2007-2009
- Chairman of the Central Research Committee at the national University hospital, Rigshospitalet 2009-2014
- Advisory Board member for Research for the Capital Region (2012- 2013)
- Evaluation board for research funds donated by the Capital Region 2010-2013
- Evaluation board for research funds to collaborative projects between Odense University Hospital and Rigshospitalet
- The Postgraduate Education Committee of the Danish Neurological Society 1998-2004. Chairman of the committee 2001 – 2004
- The steering group for the Danish Consortium for Neuromuscular diseases
- Coordinator of a multicenter clinical database and clinical trial in McArdle disease (EU-sponsored).
- Board member of Valdemar Beck og hustru Marie Beck, født Tiedmanns, Mindelegat (2002- present)
- Organizer (delkursusleder) and teacher at the yearly course on muscle diseases for upcoming specialists in Neurology
- Acting chairman of the department of neurology for several months in the period from 1999 to 2006
- Director of the Neuromuscular Clinic at Rigshospitalet, since 2000
- Director of the Neuromuscular Research Unit at Rigshospitalet, since 1998
- Participating or chairing the selection committee for multiple applications for full and associate professorships at the Medical Faculty, University of Copenhagen, and consultant neurologists at Departments of neurology in Denmark
- Member of three international consortia producing guidelines for different muscle diseases
- Vice-chair of the ethics committee D of the Capital Region (2009-2011)
- Board member of the scientific committee of the European Neuromuscular Centre (2004-2011)
- Member of the editorial Board for Neuromuscular Disorders (2008-now)
- Member of the editorial Board for Journal of Neuromuscular Diseases (2013- now)
- Member of the editorial Board for Acta Neurologica Scandinavica (2019-now)
- Co-founder and member of the steering committee for the Global FKRP registry (www.fkrp-registry.org)
- Chairman of the steering committee for two multicenter drug trial in muscular dystrophies
- Member of the Scientific panel for the Danish Medical Journal (Ugeskrift for Læger) 2007-2012
- Organizer and faculty (on scientific committee) at several international conferences
- Chairman for the neuromuscular task force under “Sundhedsfagligt Råd for Neurologi og Neurofysiologi” in the Capital Region of Denmark

- Member of the executive committee for World Muscle Society (2016-now)
- Chairman of the program committee for World Muscle Society (2021-now)
- Member on more than 60 advisory boards for the pharma industry
- Invited lecturer at international meetings, hospitals and pharma industries more than 150 times
- Chairman at international and national scientific meetings more than 50 times
- Founder and head of the Copenhagen Neuromuscular Center at the National Hospital, Rigshospitalet, University of Copenhagen since 1998.
- Host and organizer for Steps Forward meeting on Pompe disease in Copenhagen 2018 (300 participants) and 2019 World Muscle Society meeting in Copenhagen (1000 participants) and 6 ENMC workshops in Amsterdam.

Experience as assessor of scientific work

Regular reviewer for the following science journals:

New England Journal of Medicine
The Lancet
Lancet Neurology
Annals of Neurology
Neurology
Brain
Nature Clinical Practice Neurology
Journal of Neuropathology and Experimental Neurology
Journal of Applied Physiology
American Journal of Physiology
Muscle and Nerve
Neuropediatrics
Journal of Neurology, Neurosurgery & Psychiatry
Experimental Physiology
Scandinavian Journal of Medicine & Science in Sports
European Journal of Neurology
Acta Neurologica Scandinavica
Ugeskrift for Læger
Acta Physiologica Scandinavica
European Journal of Clinical Investigation
Acta Pediatrica
Acta Anesthesiologica
International Journal of Sports Medicine
Antiviral Therapy
GeneReviews (netbaseret opslagsværk)
Gastroenterology
BMC Musculoskeletal Disorders

Archives of Physical Medicine and Rehabilitation
Clinical Physiology and Functional Imaging
British Medical Bulletin
Journal of the Neurological Sciences
Neurogenetics
Neuromuscular Disorders
European Journal of Applied Physiology
Molecular Genetics and Metabolism
Expert Opinion on Medical Diagnostics
BBA - Molecular Basis of Disease
Journal of Neurology
Skeletal Muscle
Revue Neurologique

Acted as opponent (reviewer) and chairman for PhD-theses in Denmark, France, Sweden, Norway, Finland, Holland and South Africa 22 times.

Regular reviewer for international granting agencies related to neuromuscular diseases;

- Comitatio Telethon in Italy
- Muscular Dystrophy Campaign in the UK
- Clinical Research and Development Committee (CRDC) of UCLH Charities and the Medical School Bloomsbury campus, London, UK
- Princes Beatrix Fonds, Haag, Holland
- The National Science Center, Poland
- The Scientific Committee of the Association Française contre les Myopathies in France).

Reviewer for national granting agencies;

- Board member of the Valdemar Beck og hustru Marie Becks Mindelegat
- Chairman of the central research committee for Rigshospitalet
- Board member of the evaluation committee for research funds supporting collaborative projects between Odense University Hospital and Rigshospitalet
- Board member of the evaluation committee for funds in the Capital Region of Denmark
- Board member of The Lundbeck Research foundation for scholarships in neurology 2016-2022.

Experience as supervisor of students and younger doctors

- Principal supervisor for 2 doctoral theses (DMSci) and 27 PhDs from my center

- Current principal supervisor for 6 PhD students

- Since 1996, Supervisor (tutor) for younger doctors in neurology training at the department of
  neurology, Rigshospitalet.

- Supervisor for more than of more than 45 bachelor and master student projects at the medical faculty.

Teaching experience

Employed by the Medical Faculty as Instructor of gross anatomy, histology and physiology (from 1982-1986), teaching medical students in their 2nd and 3rd year of medical school.

Teacher at specialist courses (A-kurser) for paediatricians, rheumatologists, clinical geneticists, and ophthalmologists, for doctors in training to become specialists in their field (from 2000 to now).

Teacher and organizer of the yearly course (A-kursus) "Neuromuscular diseases", for neurologists in training (from 1995 to now).

Invited teacher (Faculty) at teaching courses associated with the annual meetings of the American Academy of Neurology (AAN) and European Neurological Society (ENS), teaching on aspects of muscle disease.

Faculty at the teaching course at the World Muscle Society meetings 2018-now.

Delivered in excess of 150 talks at international Neuromuscular scientific meetings.

Associate professor of neurology since 2001, and professor since 2007, and as part of this job been responsible for;

- Planning and performing neurology training of medical students in the department
- Giving lectures to students
- Arranging and performing examinations of medical students
- Giving last-year medical students classes in "acute medicine"
- Evaluating foreign doctors for authorization in Denmark
- Lecturer at other medically oriented schools (Folkesundhedsvidenskab, idrætsstuderende and human biologer)
- Teacher at multiple PhD courses in France, Sweden and Denmark

Field trips, and extended stays at other institutions

1986: One-week visit in Anton Steffens laboratory in Groningen Holland to learn stereotactic implantation techniques on rats.

1987-88: 1½-year stay as research fellow at Department of Internal Medicine, Moss Heart Center, University of Texas, Southwestern Medical Center, Dallas, USA

1992-now: More than 6 months stay in professor Ron Haller's neuromuscular laboratory in Dallas, Texas, learning research and diagnostic techniques used for evaluation of muscle diseases.

1995-97: 2-4 hour weekly studies of histological techniques in Professor Henning Schmalbruch's laboratory at the Panum Institute, Copenhagen.

1996: One-week visit to the neuromuscular center, headed by Professor Andrew Engel, at the Mayo Clinic, Rochester, Minnesota, to learn about how the center is organized, and to learn histological techniques.

1999: One-week visit to the neuromuscular center, headed by Professor Jerry Mendell, Columbus Ohio, to learn about how the center is organized, and to learn histological techniques

2001: Three-days visit to the neuromuscular center (Istituto Giannina Gaslini) in Genova, Italy, invited by Drs. Claudio Bruno and Carlo Minetti.

2005: Visiting professor (Vesalius) for one week by invitation of the University Nijmegen Hospital, visiting the Neuromuscular Centre, University Hospital, Nijmegen, Holland.

2009: Visiting professor at the 31st Annual Carrel-Krusen Neuromuscular Symposium, Dallas Texas

Awards and appointments

1995: Receiver of the Mogens Fog Award for best lecture at the Annual Meeting of the Danish Neurological Society.

Appointed specialist in Neurology, Oct. 1st, 1996.

Awarded the Roche price for research in muscle diseases, at the Annual Meeting of the Danish Neurological Society, 1998.

Appointed Doctor of Medical Science (dr. med.) at the Medical Faculty at the University of Copenhagen, November 2000.

Declared qualified for a full professorship in neurology, in 2004, by the Medical Faculty at University of Copenhagen.

Awarded the Johan Quentin and Wife's price for achievements in research concerning muscle diseases, March 2007.

Appointed professor of Neuromuscular diseases, University of Copenhagen, 2007.

Scientific activities

Our center publishes more than 50 peer-reviewed scientific publications yearly.

We have more than 50 projects ongoing, most with international collaborators.

We have 25 ongoing clinical trials with the pharma industry in neuromuscular diseases.

I have published 447 scientific publications (403 on PubMed) and my H-index is 65 (Google scholar).

PUBLICATION LIST

FOR

JOHN VISSING

Original articles

1. Vissing J, Ohkuwa T, Ploug T, Galbo H. Effect of prior immobilization on muscular glucose clearance in resting and running rats. **Am J Physiol** 1988; 255: E456-E462.

2. Vissing J, Sonne B, Galbo H. Role of metabolic feedback regulation in glucose production of running rats. **Am J Physiol** 1988; 255: R400-R406.

3. Vissing J, Sonne B, Galbo H. Regulation of hepatic glucose production in running rats studied by glucose infusion. **J Appl Physiol** 1988; 65: 2552-2557.

4. Vissing J, Wallace JL, Galbo H. Effect of liver glycogen content on glucose production in running rats. **J Appl Physiol** 1989; 66: 318-322.

5. Vissing J, Wallace JL, Scheurink AJW, Galbo H, Steffens AB. Ventromedial hypothalamic regulation of hormonal and metabolic responses to exercise. **Am J Physiol** 1989; 256: R1019-1026.

6. Vissing J, Iwamoto GA, Rybicki KJ, Galbo H, Mitchell JH. Mobilization of glucoregulatory hormones and glucose by hypothalamic locomotor centers. **Am J Physiol** 1989; 257: E722-E728.

7. Vissing J, Wilson LB, Mitchell JH, Victor RG. Static muscle contraction reflexly increases adrenal sympathetic nerve activity in rats. **Am J Physiol** 1991; 261: R1307-R1312.

8. Vissing J, Lewis SF, Galbo H, Haller RG. Effect of deficient muscular glycogenolysis on extramuscular fuel production in exercise. **J Appl Physiol** 1992; 72: 1773-1779.

9. Wiersma MML, Vissing J, Steffens AB, Galbo H. Effects of glucose infusion on hormone secretion and hepatic glucose production during heavy exercise. **Am J Physiol** 1993; 265: R1333-R1338.

10. Vissing J, Iwamoto GA, Fuchs IE, Galbo H, Mitchell JH. Reflex control of glucoregulatory exercise responses by group III and IV muscle afferents. **Am J Physiol** 1994; 266: R824-R830.

11. Dijk van G, Vissing J, Steffens AB, Galbo H. Effect of anaesthetizing the region of the paraventricular hypothalamic nuclei on energy metabolism during exercise in the rat. **Acta Physiol Scand** 1994; 151: 165-172.

12. Wiersma MML, Vissing J, Mikines KJ, Steffens AB, Galbo H. Effect of liver denervation on glucose production during running in guinea pigs. **Am J Physiol** 1995; 268: R72-R77.

13. Ploug T, Ohkuwa T, Handberg Å, Vissing J, Galbo H. Effect of immobilization on glucose transport and glucose transporter expression in rat skeletal muscle. **Am J Physiol** 1995; 268: E980-E986.

14. Vissing J, Andersen M, Diemer NH. Exercise-induced changes in local cerebral glucose utilization in the rat. **J Cereb Blood Flow Metab** 1996; 16: 729-736.

15. Vissing J, Galbo H, Haller RG. Paradoxically enhanced glucose production during exercise in humans with blocked glycolysis due to muscle phosphofructokinase deficiency. **Neurology** 1996; 47: 766-771.

16. Vissing J, Galbo H, Haller RG. Exercise fuel mobilization in mitochondrial myopathy: A metabolic dilemma. **Ann Neurol** 1996; 40: 655-662.

17. Haller RG, Clausen T, Vissing J. Reduced levels of skeletal muscle Na^+-K^+-ATPase in McArdle disease. **Neurology** 1998; 50: 37-40.
(Se også editorial om artiklen i samme udgave; side 6-7).

18. Vissing J, Salamon MB, Arlien-Søborg P, Nørby S, Manta P, DiMauro S, Schmalbruch H. A new mitochondrial $tRNA^{Met}$ gene mutation in a patient with dystrophic muscle and exercise intolerance. **Neurology** 1998; 50: 1875-1878.

19. Vissing J, Vissing SF, MacLean DA, Saltin B, Quistorff B, Haller RG. Sympathetic activation in exercise is not dependent on muscle acidosis: Direct evidence from studies in metabolic myopathies. **J Clin Invest** 1998; 101: 1654-1660.

20. MacLean D, Vissing J, Vissing SF, Haller RG. Oral branched chain amino acids do not improve exercise capacity in McArdle disease. **Neurology** 1998; 51: 1456-1459.

21. Vissing J, Schmalbruch H, Haller RG, Clausen T. Muscle phosphoglycerate mutase deficiency with tubular aggregates: Effect of dantrolene. **Ann Neurol** 1999; 46: 274-277.

22. Swiatkowski K, Dellamano LM, Vissing J, Rybicki KJ, Kozlowski GP, Iwamoto GA. Differential effects from parapyramidal region and rostral ventrolateral medulla mediated by substance P. **Am J Physiol** 1999; 277: R1120-R1129.

23. Olsen DB, Langkilde AR, Schmalbruch H, Vissing J. Diagnostic challenges in combined multiple sclerosis and centronuclear myopathy. **Eur J Neurol** 2000; 7: 567-571.

24. Colding-Jørgensen E, Vissing J. Visual impairment in anti GQ1b positive Miller Fisher Syndrome. **Acta Neurol Scand**, 2001; 103: 259-260.

25. Vissing J, Gansted U, Quistorff B. Exercise intolerance in mitochondrial myopathy is not related to lactic acidosis. **Ann Neurol** 2001; 49: 672-676.

26. Steensberg A, Vissing J, Pedersen BK. Lack of IL-6 production during exercise in patients with mitochondrial myopathy. **Eur J Appl Physiol** 2001; 84: 155-157.

27. Wibrand F, Ravn K, Schwartz M, Rosenberg T, Horn N, Vissing J. Multisystem disorder associated with a missense mutation in the mitochondrial cytochrome *b* gene. **Ann Neurol** 2001; 50: 540-543.

28. Vissing J, MacLean DA, Vissing SF, Saltin B, Haller RG. The exercise metaboreflex is maintained in the absence of muscle acidosis: insights from muscle microdialysis in humans with McArdle's disease. **J Physiol** 2001; 537: 641-649.
(Se også editorial om artiklen i samme udgave; side 331)

29. Jensen TD, Kazemi- Esfarjani P, Skomorowska E, Vissing J. A forearm exercise screening test for mitochondrial myopathy. **Neurology** 2002; 58: 1533-1538.

30. Nielsen JN, Vissing J, Wojtaszewski JFP, Haller RG, Begum N, Richter EA. Decreased insulin action in skeletal muscle from patients with McArdle's disease. **Am J Physiol (Endocrinol Metab)** 2002; 282: E1267-E1275.

31. Nielsen JN, Wojtaszewski JFP, Haller RG, Hardie G, Kemp B, Richter EA, Vissing J. Role of 5'AMP-activated protein kinase in glycogen synthase activity and glucose utilization: insights from patients with McArdle's disease. **J Physiol (Lond)** 2002; 541: 979-989.

32. Kazemi-Esfarjani P, Skomorowska E, Jensen TD, Haller RG, Vissing J. A nonischemic forearm exercise test for McArdle disease. **Ann Neurol** 2002; 52: 153-159.

33. Schwartz M, Vissing J. Paternal inheritance of mitochondrial DNA. **N Engl J Med** 2002; 347: 576-580.
(Se også editorial om artiklen i samme udgave; side 609-612).

34. Haller RG, Vissing J. Spontaneous "second wind" and glucose-induced second "second wind" in McArdle disease - Oxidative mechanisms. **Arch Neurol** 2002; 59: 1395-1402.

35. Vissing J, Ravn K, Danielsen ER, Wibrand F, Dunø M, Wevers RA, Schwartz M. Multiple mtDNA deletions with features of MNGIE. **Neurology** 2002; 59: 926-929.

36. Ørngreen MC, Olsen DB, Vissing J. Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. **Neurology** 2002; 59: 1046-1051.

37. Ørngreen MC, Gideon P, Pedersen HB, Olsen DB, Vissing J. Juvenil asymmetrisk segmental spinal muskelatrofi; en sjælden form for motorneuronsygdom. **Ugeskr Læger** 2002; 164: 4073-4075.

38. Taivassalo T, Jensen TD, Kennaway N, DiMauro S, Vissing J, Haller RG. The spectrum of exercise intolerance in mitochondrial myopathies: a study of 40 patients. **Brain** 2003; 126: 413-423.

39. Jeppesen TD, Olsen DB, Vissing J. Cycle ergometry is not a sensitive diagnostic test for mitochondrial myopathy. **J Neurol** 2003; 250: 293-299.

40. Colding-Jørgensen E, Dunø M, Schwartz M, Vissing J. Decrement of compound muscle action potential is related to mutation type in myotonia congenita. **Muscle Nerve** 2003; 27: 449-455.

41. Goethem GV, Schwartz M, Löfgren A, Dermaut B, Van Broeckhoven C, Vissing J. Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. **Eur J Hum Genet** 2003; 11: 547-549.

42. Jeppesen TD, Schwartz M, Olsen DB, Vissing J. Oxidative capacity correlates with muscle mutation load in mitochondrial myopathy. **Ann Neurol** 2003; 54: 86-92.

43. Ørngreen MC, Ejstrup R, Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. **Neurology** 2003; 61: 559-561.

44. Antonicka H, Ogilvie I, Taivassalo T, Haller RG, Vissing J, Kennaway NG, Shoubridge EA. Identification and characterization of a common set of Complex I assembly intermediates in mitochondria from patients with Complex I deficiency. **J Biol Chem** 2003; 278: 43081-43088.

45. JeppesenTD, Schwartz M, Hansen K, Danielsen ER, Wibrand F, Vissing J. Late onset of stroke-like episode associated with a 3256C→T point mutation of mitochondrial DNA. **J Neurol Sci** 2003; 214: 17-20.

46. Schwartz M, Vissing J. Paternel nedarvning af mitokondrielt DNA. **Ugeskr Læger** 2003; 165: 3627-3630.

47. Ørngreen MC, Zacho M, Herbert A, Laub M, Vissing J. Patients with severe muscle wasting are prone to develop hypoglycemia during fasting. **Neurology** 2003; 61: 997-1000.

48. Vissing J, Haller RG. A diagnostic cycle test for McArdle's disease. **Ann Neurol** 2003; 54: 539-542.

49. Olsen DB, Langkilde AR, Ørngreen MC, Rostrup E, Schwartz M, Vissing J. Muscle structural changes in mitochondrial myopathy relate to genotype. **J Neurol** 2003; 250: 1328-1334.

50. Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. **N Engl J Med** 2003; 349: 2503-2509.
(Se også editorial om artiklen i samme udgave; side 2481-2482).

51. Grunnet M, Jespersen T, Colding-Jørgensen E, Schwartz M, Klaerke DA, Vissing J, Olesen SP, Dunø M. Characterization of two new dominant ClC-1 channel mutations associated with myotonia. **Muscle Nerve** 2003; 28: 722-732.

52. Haller RG, Vissing J. No spontaneous second wind in muscle phosphofructokinase deficiency. **Neurology** 2004; 62: 82-86.

53. Schwartz M, Vissing J. No evidence for paternal inheritance of mtDNA in patients with sporadic mtDNA mutations. **J Neurol Sci** 2004; 218: 99-101.

54. Kraytsberg Y, Schwartz M, Brown TA, Ebralidse K, Kunz WS, Clayton DA, Vissing J, Khrapko K. Recombination of human mitochondrial DNA. **Science** 2004; 304: 981
(online supporting material; www.sciencemag.org/cgi/content/full/304/5673/981/DC1).

55. Ørngreen MC, Nørgaard MG, Sacchetti M, van Engelen BG, Vissing J. Fuel utilization in patients with very long-chain acyl-CoA dehydrogenase deficiency. **Ann Neurol** 2004; 56: 279-282.

56. Dunø M, Colding-Jørgensen E, Grunnet M, Jespersen T, Vissing J, Schwartz M. Difference in allelic expression of the CLCN1 gene and the possible influence on the myotonia congenita phenotype. **Eur J Hum Genet** 2004; 12: 738-743.

57. Vissing J, Quistorff B, Haller RG. Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency. **Arch Neurol** 2005; 62: 1440-1443.

58. Olsen DB, Ørngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. **Neurology** 2005; 64: 1064-1066.

59. Ørngreen MC, Dunø M, Christensen E, Sacchetti M, Schwartz M, Vissing J. Fuel utilization in subjects with carnitine palmitoyltransferase II gene mutations. **Ann Neurol** 2005; 57: 60-66.

60. Anthonisen M, Toft R, Rønager J, Vissing J. Patientgrundlag og evaluering af undersøgelser i en neuromuskulær klinik gennem tre år. **Ugeskr Læger** 2005; 167: 2405-2408.

61. Østergaard E, Wibrand F, Ørngreen MC, Vissing J, Horn N. Impaired energy metabolism and abnormal muscle histology in mut\- methylmalonic aciduria. **Neurology** 2005; 65: 931-934.

62. Schwartz M, Hertz JM, Sveen ML, Vissing J. **LGMD2I presenting with a characteristic Duchenne or Becker dystrophy phenotype**. **Neurology** 2005; 64: 1635-1637.
(se også editorial om artiklen i samme udgave; side 1498-1499)

63. Ørngreen, MC, Olsen DB, Vissing J. Aerobic training in patients with myotonic dystrophy type I. **Ann Neurol** 2005; 57: 754-757.

64. Sveen ML, Schwartz M, Vissing J. High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. **Ann Neurol** 2006; 59: 808-815.

65. Frederiksen AL, Andersen PH, Kyvik KO, Jeppesen TD, Vissing J, Schwartz M. Tissue specific distribution of the 3243A>G mtDNA mutation. **J Med Genet** 2006; 43: 671-677.

66. Olsen DB, Gideon P, Jeppesen TD, Vissing J. Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI. **J Neurol** 2006; 253: 1437-1441.

67. Colding-Jørgensen E, Dunø M, Vissing J. Autosomal dominant monosymptomatic myotonia permanens. **Neurology** 2006; 67: 153-155.

68. Haller RG, Wyrick P, Taivassalo T, Vissing J. Aerobic conditioning: An effective therapy in McArdle disease. **Ann Neurol** 2006; 59: 922-928.

69. Andersen ST, Dunø M, Schwartz M, Vissing J. Do carriers of *PYGM* mutations have symptoms of McArdle disease? **Neurology** 2006; 67: 716-718.

70. Jeppesen TD, Schwartz M, Frederiksen AL, Wibrand F, Olsen DB, Vissing J. Muscle phenotype and mutation load in 51 persons with the 3243A>G mitochondrial DNA mutation. **Arch Neurol** 2006; 63: 1701-1706.

(se også editorial om artiklen i samme udgave; side 1679-1680)

71. Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Dunø M, Hauerslev S, Vissing J. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. **Brain** 2006; 129: 3402-3412.

72. Sveen ML, Jeppesen TD, Hauerslev S, Krag TO, Vissing J. Endurance training: An effective and safe treatment for patients with LGMD2I. **Neurology** 2007; 68: 59-61.

73. Ostergaard E, Hansen FJ, Sorensen N, Duno M, Vissing J, Larsen PL, Faeroe O, Thorgrimsson S, Wibrand F, Christensen E, Schwartz M. Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by *SUCLA2* mutations. **Brain** 2007; 130: 853-861.
(se også editorial om artiklen i samme udgave; side 606-609).

74. Schwartz M, Dunø M, Palle AL, Krag TO, Vissing J. Deletion of exon 16 in the dystrophin gene is not associated with disease. Hum Mutat 2007; 28(2): 205.

75. Jeppesen TD, Quistorff B, Wibrand F, Vissing J. ^{31}P-MRS of muscle is not a sensitive diagnostic test for mitochondrial myopathy. **J Neurol** 2007; 254: 29-37.

76. Yavuz H, Özel A, Christensen M, Christensen E, Schwartz M, Elmacı M, Vissing J. Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. **Arch Neurol** 2007; 64: 435-438.

77. Ørngreen MC, Nørgaard MG, van Engelen BG, Vistisen B, Vissing J. Effects of IV glucose and oral medium chain triglyceride in patients with VLCAD deficiency. **Neurology** 2007; 69: 313-315.

78. Ørngreen MC, Schelhaas HJ, Jeppesen TD, Akman HO, Wevers RA, Andersen ST, Laak HT, van Diggelen O, DiMauro S, Vissing J. Is muscle glycogenolysis impaired in X-linked phosphorylase *b* kinase deficiency? **Neurology** 2008; 70: 1876-1882.
(Se også editorial om artiklen i samme udgave; side 1872-1873).

79. Hengstman GJ, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, Slott Jensen H, Van Engelen BG, Van den Hoogen FH. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. **Eur Neurol** 2008; 59: 159-163.

80. Jeppesen TD, Schwartz M, Colding-Jorgensen E, Krag T, Hauerslev S, Vissing J. Phenotype and clinical course in a family with a new *de novo* Twinkle gene mutation. **Neuromuscul disord** 2008; 18: 306-309.g

81. Hjermind LE, Vissing J, Asmus F, Krag T, Lochmüller H, Walter MC, Erdal J, Blake DJ, Nielsen JE. No muscle involvement in myoclonus-dystonia caused by ε-sarcoglycan gene mutations. **Eur J Neurol** 2008; 15: 525-529.

82. Duno M, Sveen ML, Schwartz M, Vissing J. cDNA analyses of *CAPN3* enhance mutation detection and reveal a low prevalence of LGMD2A patients in Denmark. **Eur J Hum Genet** 2008; 16: 935-940.

83. Andersen ST, Haller, RG, Vissing J. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. **Arch Neurol** 2008; 65: 786-789.

84. Sveen ML, Thune JJ, Køber L, Vissing J. Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy. **Arch Neurol** 2008; 65: 1196-1201.

85. Andersen ST, Vissing J. Carbohydrate- and protein-rich diets in McArdle disease: Effects on exercise capacity. **J Neurol Neurosurg Psychiatry** 2008; 79: 1359-1363.

86. Sveen ML, Jeppesen TD, Hauerslev S, Køber L, Krag TO, Vissing J. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. **Brain** 2008; 131: 2824-2831.

(Se også editorial om artiklen i samme udgave; side 2809-2812, samt editorial om artiklen i Nature Clinical Practice Neurology 2008;4;638.

87. Naini A, Toscano A, Musumeci O, Vissing J, Akman HO, DiMauro S. Muscle phosphoglycerate mutase (PGAM) deficiency revisited. **Arch Neurol** 2009; 66(3): 394-398.

88. Preisler N, Andersen G, Thøgersen F, Crone C, Jeppesen TD, Vissing J. Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease). **Neurology** 2009; 72: 317-323.

89. Ørngreen MC, Jeppesen TD, Andersen ST, Taivassalo T, Hauerslev S, Preisler N, Haller RG, van Hall G, Vissing J. Fat metabolism during exercise in patients with McArdle disease. **Neurology** 2009; 72: 718-724.

90. Jeppesen TD, Ørngreen MC, van Hall G, Haller RG, Vissing J. Fat metabolism during exercise in patients with mitochondrial disease. **Arch Neurol** 2009; 66(3): 365-370.

91. Andersen ST, Jeppesen TD, Taivassalo T, Sveen ML, Heinicke K, Haller RG, Vissing J. Effect of changes in fat availability on exercise capacity in McArdle disease. **Arch Neurol** 2009; 66: 762-766.

92. Duno M, Quinlivan R, Vissing J, Schwartz M. High-resolution melting facilitates mutation screening of *PYGM* in patients with McArdle disease. **Ann Hum Genet** 2009; 73: 292-297.

93. Vissing J, Duno M, Schwartz M, Haller RG. Splice mutations preserve myophosphorylase activity that ameliorates the phenotype in McArdle disease. **Brain** 2009; 132: 1545-1552.

94. Frederiksen AL, Jeppesen TD, Vissing J, Schwartz M, Kyvik KO, Schmitz O, Poulsen PL, Andersen PH. High prevalence of impaired glucose homeostasis and myopathy in a- and oligosymptomatic 3243A>G mtDNA mutation-positive subjects. **J Clin Endocrinol Metab** 2009; 94: 2872-2879.

95. Stojkovic T, Vissing J, Petit F, Piraud M, Orngreen MC, Andersen G, Claeys KG, Wary C, Hogrel JY, Laforêt P. Muscle glycogenosis due to phosphoglucomutase 1 deficiency. **N Engl J Med** 2009; 361: 425-427.

96. Jeppesen TD, Duno M, Schwartz M, Krag T, Rafiq J, Wibrand F, Vissing J. Short- and long-term effects of endurance training in patients with mitochondrial myopathy. **Eur J Neurol** 2009; 16: 1336-1339.

97. Svenstrup K, Bross P, Koefoed P, Hjermind LE, Eiberg H, Born AP, Vissing J, Gyllenborg J, Nørremølle A, Hasholt L, Nielsen JE. Sequence variants in *SPAST, SPG3A* and *HSPD1* in hereditary spastic paraplegia. **J Neurol Sci** 2009; 284: 90-95.

98. Wibrand F, Jeppesen TD, Frederiksen AL, Olsen DB, Duno M, Schwartz M, Vissing J. Limited diagnostic value of enzyme analysis in patients with mitochondrial tRNA mutations. **Muscle Nerve** 2010; 41; 607-613.

99. Born AP, Müller K, Marquart HV, Heilmann C, Schejbel L, Vissing J. Myositis in Griscelli syndrome type 2 treated with hematopoietic cell transplantation. **Neuromuscl Disord** 2010; 20: 136-138.

100. Quinlivan R, Buckley J, James M, Twist A, Ball S, Duno M, Vissing J, Bruno C, Cassandrini D, Roberts M, Winer J, Rose M, Sewry C. McArdle disease: A clinical review. **J Neurol Neurosurg Psychiatry** 2010; 81: 1182-1188.

101. Gavassini BF, Carboni N, Nielsen JE, Danielsen ER, Thomsen C, Svenstrup K, Bello L, Maioli MA, Marrosu G, Ticca AF, Mura M, Marrosu MG, Soraru G, Angelini C, Vissing J, Pegoraro E. Clinical and molecular characterization of limb girdle muscular dystrophy due to *LAMA2* mutations. **Muscle Nerve** 2011; 44: 703-709.

102. Anvar SY, hoen PA, Venema A, van der Sluijs B, van Engelen B, Snoeck M, Vissing J, Trollet C, Dickson G, Chartier A, Simonelig M, van Ommen GJB, van der Maarel SM, Raz V. Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients. **Skelet Muscle** 2011; 1: 15.

Online: http://www.skeletalmusclejournal.com/content/1/1/15

103. Møller LB, Horn N, Jeppesen TD, Vissing J, Wibrand F, Jennum P, Ott P. Clinical presentation and mutations in Danish patients with Wilson disease. **Eur J Hum Genet** 2011; 19: 935-941.

104. Krag TO, Hauerslev S, Sveen ML, Schwartz M, Vissing J. Level of muscle regeneration in limb-girdle muscular dystrophy type 2I relates to genotype and clinical severity. **Skelet Muscle** 2011;1:31.

Online: http://www.skeletalmusclejournal.com/content/1/1/31

105. Witting N, Duno M, Vissing J. Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype. **Acta Myol** 2011; 30(3): 182-184.

106. Laforêt P, Orngreen MC, Preisler N, Andersen G, Vissing J. Blocked muscle fat oxidation during exercise in neutral lipid storage disease. **Arch Neurol** 2012; 69: 530-533.

107. Orngreen MC, Arlien-Søborg P, Duno M, Hertz JM, Vissing J. Endocrine function in 97 patients with myotonic dystrophy type 1. **J Neurol** 2012; 259(5): 912-920.

108. Jeppesen TD, Vissing J, González- Alonso J. Influence of erythrocyte oxygenation and intravascular ATP on resting and exercising skeletal muscle blood flow in humans with mitochondrial myopathy. **Mitochondrion** 2012; 12: 414-422.

109. Hauerslev S, Sveen ML, Duno M, Angelini C, Vissing J, Krag TO. Calpain 3 is important for

muscle regeneration: Evidence from patients with limb girdle muscular dystrophies. BMC

Musculoskelet Disord 2012; 13(1): 43.

110. Böhm J, Biancalana V, DeChene ET, Bitoun M, Pierson CR, Schaefer E, Karasoy H, Dempsey MA, Klein F, Dondaine N, Kretz C, Haumesser N, Poirson C, Toussaint A, Greenleaf RS, Barger MA, Mahoney LJ, Kang PB, Zanoteli E, Vissing J, Witting N, Echaniz-Laguna A, Wallgren-Pettersson C, Dowling J, Merlini L, Oldfors A, Bomme-Ousager L, Melki J, Krause A, Jern C, Oliveira ASB, Petit F, Jacquette A, Chaussenot A, Mowat D, Leheup B, Cristofano M, Aldea JP, Michel F, Furby A, Llona JEB, van Coster R, Bertini E, Urtizberea JA, Drouin-Garraud V, Béroud C, Prudhon B, Bedford HM, Mathews K, Erby LAH, Smith SA, Roggenbruck J, Crowe CA, Spitale AB, Johal SC, Amato AA, Demmer LA, Jonas J, Darras BT, Bird TD, Laurino M, Welt SI, Trotter C, Guicheney P, Das S, Mandel J-L, Beggs AH, Laporte J. Mutation spectrum in the large GTPase dynamin 2 (DNM2) and genotype/phenotype correlation in autosomal dominant centronuclear myopathy. **Hum Mutat** 2012; 33: 949-959.

111. Preisler N, Orngreen MC, Echaniz-Laguna A, Laforet P, Lonsdorfer-Wolf E, Doutreleau S, Geny B, Akman HO, Dimauro S, Vissing J. Muscle phosphorylase kinase deficiency; a neutral metabolic variant or a disease? **Neurology** 2012; 78: 265-268.

112. Preisler N, Laforêt P, Madsen KL, Hansen RS, Lukacs, Z, Orngreen MC, Lacour A, Vissing J. Fat and carbohydrate metabolism during exercise in late-onset Pompe disease. **Mol Genet Metab** 2012; 107; 462-468.

113. Werlauff U, Vissing J, Steffensen BF. Change in muscle strength over time in spinal muscular atrophy types II and III. A long-term follow-up study. **Neuromuscl Disord** 2012; 22: 1069-1074.

114. Witting N, Dunø M, Born P, Vissing J. LGMD2L with bone affection: Overlapping phenotypes of dominant and recessive ANO5-induced disease. **Muscle Nerve** 2012; 46: 829-830.

115. Mathiesen P, Ørngreen MC, Vissing J, Andersen LB, Herlin T, Nielsen S. Aerobic fitness after juvenile dermatomyositis - a long-term follow-up study. **Rheumatology** 2013; 52: 287-295.

116. Andersen G, Orngreen MC, Preisler N, Colding-Jørgensen E, Clausen T, Duno M, Jeppesen TD, Vissing J. Muscle phenotype in patients with myotonic dystrophy type 1. **Muscle Nerve** 2013; 47: 409-415.

117. Witting N, Duno M, Vissing J. Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2. **Neuromuscl Disord** 2013; 23: 25-28.

118. Sveen ML, Andersen SP, Ingelsrud LH, Blichter S, Olsen NE, Jønck S, Krag TO, Vissing J. Resistance training in patients with Limb Girdle and Becker muscular dystrophies. **Muscle Nerve** 2013; 47: 163-169.

119. Madsen KL, Preisler N, Orngreen MC, Andersen SP, Olesen JH, Lund AM, Vissing J. Patients with medium-chain acyl-Coenzyme A-dehydrogenase deficiency have impaired oxidation of fat during exercise but no effect of L-carnitine supplementation. **J Clin Endocrinol Metab** 2013; 98(4):1667-1675.

120. Vissing CR, Duno M, Olesen JH, Rafiq J, Risom L, Christensen E, Wibrand F, Vissing J. Recurrent myoglobinuria and deranged acylcarnitines due to a mutation in the mtDNA *MT-CO2* gene. **Neurology** 2013; 80: 1908-1910.

121. Hauerslev S, Ørngreen MC, Hertz JM, Vissing J, Krag TO. Regeneration and inflammation in skeletal muscle of patients with facioscapulohumeral muscular dystrophy. **Acta Neurol Scand** 2013**;** 128(3): 194-201.

122. Andersen SP, Sveen ML, Hansen RS, Madsen KL, Hansen JB, Madsen M, Vissing J. Creatine kinase response to high-intensity aerobic exercise in adult-onset muscular dystrophy. **Muscle Nerve** 2013; 48(6): 897-901.

123. Krag TO, Hauerslev S, Jeppesen TD, Duno M, Schwartz M, Vissing J. Muscle regeneration in mitochondrial myopathies. **Mitochondrion** 2013; 13: 63-70.

124. Crone C, Christiansen I, Vissing J. Myopathic EMG findings and type II muscle fiber atrophy in patients with Lambert-Eaton myasthenic syndrome. Clin Neurophys 2013; 124(9): 1889-1892.

125. Ghelli A, Marchesini A, Tropeano CV, Calvaruso MA, Iommarini L, Porcelli AM, Zanna C, Nardo VD, Martinuzzi A, Wibrand F, Vissing J, Kurelac I, Gasparre G, Selamoglu N, Daldal F, Rugolo M. The Cytochrome B p.278Y>C mutation causative of a multisystem disorder enhances superoxide production and alters supramolecular interactions of respiratory chain complexes. **Hum Mol Genet** 2013; 22: 2141-2151.

126. Preisler N, Pradel A, Husu E, Madsen KL, Becquemin MH, Mollet A, Labrune P, Petit F, Hogrel JY, Jardel C, Maillot F, Vissing J, Laforêt P. Exercise intolerance in glycogen storage disease type III: Weakness or energy deficiency? **Mol Genet Metab** 2013; 109(1): 14-20.

127. Willis TA, Hollingsworth KG, Coombs A, Sveen M-L, Andersen S, Stojkovic T, Eagle M, Mayhew A, de Sousa PL, Dewar L, Morrow JM, Sinclair CDJ, Thornton JS, Bushby K, Lochmuller H, Hanna MG, Hogrel JY, Carlier PG, Vissing J, Straub V. Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. **PLoS One** 2013; 8(8): e70993. doi:10.1371/journal.pone.0070993.

128. Witting N, Duno M, Petri H, Krag T, Bundgaard H, Kober L, Vissing J. Anoctamin 5 muscular dystrophy in Denmark; genotype, phenotype, prevalence, cardiology and muscle protein expression. **J Neurol** 2013; 260(8): 2084-2093.

129. Riisager M, Duno M, Hansen FJ, Krag TO, Vissing CR, Vissing J. A new mutation of the Fukutin gene causing late onset of Limb Girdle Muscular Dystrophy. **Neuromuscl Disord** 2013; 23(7): 562-567.

130. Preisler N, Laforêt P, Echaniz-Laguna A, Orngreen MC, Lonsdorfer-Wolf E, Doutreleau S, Geny B, Stojkovic, T, Piraud M, Petit FM, Vissing J. Fat and carbohydrate metabolism during exercise in phosphoglucomutase type 1 deficiency. **J Clin Endocrinol Metab** 2013; 98: E1235-1240.

131. Jeppesen TD, Orngreen MC, van Hall G, Vissing J. Lactate metabolism during exercise in patients with mitochondrial myopathy. **Neuromuscl Disord** 2013; 23(8): 629-636.

132. Preisler N, Lukacs Z, Vinge L, Madsen KL, Husu E, Hansen RS, Duno M, Andersen H, Laub M, Vissing J. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. **Mol Metab Genet** 2013: 110(3):287-289.

133. Hauerslev S, Sveen ML, Vissing J, Krag TO. Protein turnover and cellular stress in mildly and severely affected muscles from patients with limb girdle muscular dystrophy type 2I. **PLoS One** 2013; 8(6): e66929. doi: 10.1371/journal.pone.0066929

134. Anvar SY, Raz Y, Verway N, van der Sluijs B, Venema A, Goeman JJ, Vissing J, van der Maarel SM, 't Hoen PA, van Engelen BG, Raz V. A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging. **Aging** 2013; 5: 412-426.

135. Riisager M, Mathiesen P, Vissing J, Preisler N, Ørngreen MC. Aerobic training in persons who have recovered from juvenile dermatomyositis. **Neuromuscl Disord** 2013; 23(12): 962-968.

136. Krag T, Hauerslev S, Dahlqvist J, Vissing J. Muscle biopsies off-set normal cellular signaling in surrounding musculature. **Neuromuscul Disord** 2013; 23(12): 981-985.

137. Jeppesen TD, Duno M, Risom L, Schwartz M, Wibrand F, Rafiq J, Jakobsen J, Andersen H, Krag T, Vissing J. A novel *de novo* mutation of the mitochondrial $tRNA^{lys}$ gene mt.8340G>A associated with pure myopathy. **Neuromuscl Disord** 2014; 24(2): 162-166.

138. Dahlqvist J, Voss LG, Lauridsen T, Krag TO, Vissing J. A pilot study of muscle plasma protein changes following exercise. **Muscle Nerve** 2014; 49(2): 261-266.

139. Vissing CR, Preisler N, Husu E, Prahm K, Vissing J. Aerobic training in patients with myopathy and hyperCKemia caused by anoctamin 5 deficiency. **Muscle Nerve** 2014; 50(1): 119-123.

140. Cejvanovic S, Vissing J. Muscle strength in myasthenia gravis. **Acta Neurol Scand** 2014: 129(6): 367-373.

141. Mensah A, Witting N, Duno M, Milea D, Vissing J. Delayed diagnosis of oculopharyngeal muscular dystrophy in Denmark: From initial ptosis to genetic testing. **Acta Ophthalmol** 2014; 92(3): 247-249.

142. Witting N, Duno M, Piraud M, Vissing J. Severe axial myopathy in McArdle disease. **JAMA Neurology** 2014; 71(1): 88-90.

143. Orngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforêt P. Bezafibrate in skeletal muscle fatty oxidation disorders: a randomized clinical trial. **Neurology** 2014; 82(7): 607-613.

144. Werlauff U, Højbjerg A, Firla-Holme R, Steffensen BF, Vissing J. Fatigue in patients with spinal muscular atrophy type II and congenital myopathies; evaluation of the fatigue severity scale. **Qual Life Res** 2014: 23(5); 1479-1488.

145. Mosbech MB, Olsen AS, Neess D, Ben-David O, Klitten LL, Larsen J, Sabers A, Vissing J, Nielsen JE, Hasholt L, Klein AD, Tsoory MM, Hjalgrim H, Tommerup N, Futerman AH, Møller RS, Færgeman NJ. Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsy. **Ann Clin Transl Neuro** 2014; 1(2): 88-98.

146. Citirak G, Witting N, Duno M, Werlauff U, Petri H, Vissing J. Frequency and phenotype of patients carrying *TPM2* and *TPM3* gene mutations in a cohort of 94 patients with congenital myopathy. **Neuromuscul Disord** 2014; 24(4): 325-330.

147. Willis TA, Hollingsworth KG, Coombs A, Sveen ML, Andersen S, Stojkovic T, Eagle M, Mayhew A, de Sousa PL, Dewar L, Morrow JM, Sinclair CD, Thornton JS, Bushby K, Lochmuller H, Hanna MG, Hogrel JY, Carlier PG, Vissing J, Straub V. Quantitative Magnetic Resonance Imaging in Limb-Girdle Muscular Dystrophy 2I - A Multinational Cross-sectional Study. **PLoS One** 2014; Feb 28;9(2):e90377. doi: 10.1371/journal.pone.0090377.

148. Witting N, Mensah A, Kober L, Bundgaard H, Petri H, Duno M, Milea D, Vissing J. Ocular, bulbar, limb and cardiopulmonary involvement in oculopharyngeal muscular dystrophy. **Acta Neurol Scand** 2014; 130(2): 125-130.

149. Andreassen CS, Schlütter JM, Vissing J, Andersen H. Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease – a long-term follow-up. **Mol Genet Metab** 2014; 112(1): 40-43.

150. Berthelsen MP, Husu E, Christensen SB, Prahm KP, Vissing J, Jensen BR. Anti-gravity training improves walking capacity and postural balance in patients with muscular dystrophy. **Neuromuscul Disord** 2014; 24(6): 492-498.

151. Petri H, Witting N, Ersbøll MK, Sajadieh A, Helweg-Larsen S, Duno M, Vissing J, Kober L, Bundgaard H. High prevalence of cardiac involvement in patients with myotonic dystrophy type 1; a cross-sectional cohort study. **Int J Cardiol** 2014; 174(1): 31-36.

152. Lund M, Diaz LJ, Ranthe MF, Petri H, Duno M, Juncker I, Eiberg H, Vissing J, Bundgaard H, Wohlfahrt J, Melbye M. Cardiac involvement in myotonic dystrophy: a nationwide cohort study. **Eur Heart J** 2014; 35(32): 2158-2164.

153. Lund M, Diaz LJ, Gørtz S, Feenstra B, Duno M, Juncker I, Eiberg H, Vissing J, Wohlfahrt J, Melbye M. Risk of cancer in relatives of patients with myotonic dystrophy: a population based cohort study. **Eur J Neurol** 2014; 21(9): 1192-1197.

154. Hauerslev S, Vissing J, Krag TO. Muscle atrophy reversed by growth factor activation of satellite cells in a mouse muscle atrophy model. **PLoS One** 2014; 25;9(6):e100594. doi: 10.1371/journal.pone.0100594.

155. Witting N, Kruuse C, Nyhus B, Prahm K, Citirak G, Lundgaard S, von Huth S, Vejlstrup N, Lindberg U, Krag T, Vissing J. Effect of Sildenafil on skeletal and cardiac muscle function in Becker muscular dystrophy. **Ann Neurol** 2014; 76(4): 550-557.

156. Prahm KP, Witting N, Vissing J. Decreased variability of the 6-minute walk test by heart rate correction in patients with neuromuscular disease. **PLoS One** 2014 Dec 5;9(12):e114273. doi: 10.1371/journal.pone.0114273.

157. Dahlqvist JR, Vissing CR, Thomsen C, Vissing J. Severe paraspinal muscle involvement in facioscapulohumeral muscular dystrophy. **Neurology** 2014; 83(13): 1178-1183.

158. Rue N, Vissing J, Galbo H. Insulin resistance and increased cytokine levels in patients with mitochondrial myopathy. **J Clin Endocrinol Metab** 2014; 99(10): 3757-3765.

159. Petri H, Ahtarovski K, Vejlstrup N, Vissing J, Witting N, Køber L, Bundgaard H. Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study. **J Cardiovasc Magn Reson** 2014 Aug 1;16(1):59.

160. Petri H, Sveen ML, Thune JJ, Vissing C, Dahlqvist JR, Witting N, Bundgaard H, Køber L, Vissing J. Progression of cardiac involvement in patients with limb-girdle type 2 and Becker muscular dystrophies: A 9-year follow-up study. **Int J Cardiol** 2015; 182: 403-411.

161. *Born AP, Duno M, Rafiq J, Risom L, Wibrand F, Ostergaard E, Vissing J.* **A mitochondrial tRNA^{Met} mutation causing developmental delay, exercise intolerance and limb girdle phenotype with onset in early childhood. Eur J Paediatr Neurol** 2015; 19(1): 69-71**.**

162. Levison L, Dunø M, Risom L, Toft PB, Vissing J. Differences in genetic defects morphology of eye- and limb muscles in mitochondrial myopathy. **Acta Ophthalmol** 2015; 93(4): e306-308.

163. Løkken N, Born AP, Duno M, Vissing J. *LAMA2*-related myopathy; frequency among congenital and limb-girdle muscular dystrophies. **Muscle Nerve** 2015; 52(4): 547-553.

164. Madsen KL, Hansen RS, Preisler N, Thøgersen F, Berthelsen MP, Vissing J. Training improves oxidative capacity, but not function, in spinal muscular atrophy type III. **Muscle Nerve** 2015; 52(2): 240-244.

165. Andersen G, Ørngreen MC, Preisler N, Jeppesen TD, Krag TO, Hauerslev S, van Hall G, Vissing J. Protein-carbohydrate supplements improve muscle protein balance in muscular dystrophy patients after endurance exercise: a placebo controlled crossover study. **Am J Physiol Regul Integr Comp Physiol** 2015; 308(2): R123-R130.

166. Preisler N, Laforet P, Madsen KL, Prahm KP, Hedermann G, Vissing CR, Galbo H, Vissing J. Skeletal muscle metabolism is impaired during exercise in glycogen storage disease type III. **Neurology** 2015; 84(17): 1767-1771.

167. Ostergaard E, Weraarpachai W, Ravn K, Born AP, Jønson L, Duno M, Wibrand F, Shoubridge EA, Vissing J. Mutations in *COA3* cause isolated complex IV deficiency associated with neuropathy, exercise intolerance, obesity and short stature. **J Med Genet** 2015; 52(3): 203-207.

168. Krag TO, Vissing J. A new mouse model of Limb-Girdle muscular dystrophy type 2I homozygous for the common L276I mutation mimicking the mild phenotype in humans. **J Neuropathol Exp Neurol** 2015; 74(12): 1137-1146.

169. Dahlqvist J, Orngreen M, Witting N, Vissing J. Endocrine function over time in patients with myotonic dystrophy type 1. **Eur J Neurol** 2015; 22(1): 116-122.

170. Witting N, Crone C, Duno M, Vissing J. Clinical and neurophysiological response to pharmacological treatment of DOK7 congenital myasthenia in an elderly patient. **Clin Neurol Neurosurg** 2015; 130: 168-170.

171. Werlauff U, Petri H, Witting N, Vissing J. Frequency and phenotype of myotubular myopathy amongst Danish patients with congenital myopathy older than 5 years. **J Neuromuscul Dis** 2015; 2: 167–174.

172. Semplicini C, Vissing J, Dahlqvist JR, Stojkovic T, Bello L, Witting N, Duno M, Leturcq F, Bertolin C, D'Ambrosio P, Eymard B, Angelini C, Politano L, Laforet P, Pegoraro E. Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. **Neurology** 2015; 84(17): 1772-1781.

173. Lund M, Melbye M, Diaz LJ, Duno M, Wohlfahrt J, Vissing J. Mitochondrial dysfunction and risk of cancer. **Br J Cancer** 2015; 112: 1134-1140.

174. Andersen G, Prahm KP, Dahlqvist JR, Citirak G, Vissing J. Aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy: RCT study. **Neurology** 2015 4; 85(5): 396-403.

175. Ørngreen MC, Jeppesen TD, Taivassalo T, Hauerslev S, Preisler N, Heinecke K, Haller RG, Vissing J, van Hall G. Lactate and energy metabolism during exercise in patients with blocked glycogenolysis (McArdle disease). **J Clin Endocrinol Metab** 2015; 100(8): E1096-E1104.

176. Tasca G, D'Amico A, Monforte M, Nadaj-Pakleza A, Vialle M, Fattori F, Vissing J, Ricci E, Bertini E. Muscle imaging in patients with tubular aggregate myopathy caused by mutations in STIM1. **Neuromuscl Disord** 2015; 25(11): 898-903.

177. Rafiq J, Duno M, Østergaard E, Ravn K, Vissing CR, Wibrand F, Vissing J. Exercise intolerance and myoglobinuria associated with a novel maternally inherited *MT-ND1* mutation. **JIMD Rep** 2016; 25: 65-70.

178. Guo S, Esserlind AL, Andersson Z, Frederiksen AL, Olesen J, Vissing J, Ashina M. Prevalence of migraine in persons with the 3243A>G mutation in mitochondrial DNA. **Eur J Neurol** 2016; 23(1): 175-181.

179. Witting N, Werlauff U, Duno M, Vissing J. Prevalence and phenotypes of congenital myopathy due to α-actin 1 gene mutations. **Muscle Nerve** 2016; 53(3): 388-393.

180. Andersen LK, Knak KL, Witting N, Vissing J. Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases. **Neurology** 2016; 86(5): 442-445.

181. Zaharieva IT, Thor MG, Oates EC, van Karnebeek C, Hendson G, Blom E, Witting N, Rasmussen M, Gabbett MT, Ravenscroft G, Sframeli M, Suetterlin K, Sarkozy A, D'Argenzio L, Hartley L, Matthews E, Pitt M, Vissing J, Ballegaard M, Krarup C, Slørdahl A, Halvorsen H, Ye XC, Zhang LH, Løkken N, Werlauf U, Abdelsayed M, Davis MR, Feng L, Phadke R, Sewry CA, Morgan JE, Laing NG, Vallance H, Ruben P, Hanna MG, Lewis S, Kamsteeg EJ, Männikkö R, Muntoni F. Loss-of-function

mutations in *SCN4A* cause severe foetal hypokinesia or “classical” congenital myopathy. **Brain** 2016; 139(3): 674-691.

182. Hedermann G, Marquart HV, Vissing J. Polymyositis following autologous haematopoietic stem cell transplantation. **Scand J Rheumatol** 2016; 45(5): 429-431.

183. Hedermann G, Vissing CR, Heje K, Preisler N, Witting N, Vissing J. Aerobic training in patients with congenital myopathy. **PLoS One** 2016 Jan 11;11(1): e0146036. doi: 10.1371/journal.pone.0146036.

184. Jensen BR, Berthelsen MP, Husu E, Christensen SB, Prahm KP, Vissing J. Body weight-supported training in Becker and limb girdle muscular dystrophy. **Muscle Nerve** 2016; 54(2): 239-243.

185. Krag TO, Pinós T, Nielsen TL, Brull A, Andreu AL, Vissing J. Differential muscle involvement in mice and humans affected by McArdle disease. **J Neuropathol Exp Neurol** 2016; 75(5): 441-454.

186. Vissing J, Barresi R, Witting N, Ghelue Mv, Gammelgaard L, Bindoff LA, Straub V, Lochmüller H, Hudson J, Wahl CM, Arnardottir S, Dahlbom K, Jonsrud C, Duno M. A heterozygous 21-bp deletion in *CAPN3* causes dominantly inherited limb girdle muscular dystrophy. **Brain** 2016; 139(8): 2154-2163.

187. Krag TO, Pinós T, Nielsen TL, Duran J, García-Rocha M, Andreu AL, Vissing J. Differential glucose metabolism in mice and humans affected by McArdle disease. **Am J Physiol Reg Int Comp** 2016; 311(2): R307-R314.

188. Løkken N, Hedermann G, Thomsen C, Vissing J. Contractile properties are disrupted in Becker muscular dystrophy, but not in limb girdle type 2I. **Ann Neurol** 2016; 80(3): 466-471.

189. Oestergaard ST, Stojkovic T, Dahlqvist JR, Bouchet-Seraphin C, Nectoux J, Leturcq F, Cossée M, Solé G, Thomsen C, Krag T, Vissing J. Muscle involvement in limb girdle muscular dystrophy with GMPPB deficiency (LGMD2T). **Neurol Genet** 2016 Oct 11; 2(6):e112, doi:10.1212/NXG.0000000000000112.

190. Hedermann G, Løkken N, Dahlqvist JR, Vissing J. Dysphagia is prevalent in patients with CPEO and single, large-scale deletions in mtDNA. **Mitochondrion** 2016; 32: 27-30.

191. Citirak G, Cejvanovic S, Andersen H, Vissing J. Effect of gender, disease duration and treatment on muscle strength in myasthenia gravis. **PLoS ONE** 2016 Oct 14; 11(10): e0164092. doi: 10.1371/journal.pone.0164092.

192. Riaz M, Raz Y, van der Slujis B, Dickson G, van Engelen B, Vissing J, Raz V. Cytokine genes as potential biomarkers for muscle weakness in OPMD. **Hum Mol Genet** 2016; 25(19): 4282-4287.

193. Svenstrup K, Nielsen TT, Aidt F, Rostgaard N, Duno M, Wibrand F, Vinther-Jensen T, Law I, Vissing J, Roos P, Hjermind LE, Nielsen JE. SCA28: Novel mutation in the AFG3L2 proteolytic domain causes a mild cerebellar syndrome with selective type-1 muscle fiber atrophy. **Cerebellum** 2017; 16 (1): 62-67.

194. Lindberg U, Witting N, Jørgensen SL, Vissing J, Rostrup E, Larsson HB, Kruuse C. Effects of sildenafil on cerebrovascular reactivity in patients with Becker muscular dystrophy. **Neurotherapeutics** 2017; 14(1): 182-190.

195. Dahlqvist JR, Vissing CR, Hedermann G, Thomsen C, Vissing J. Fat replacement of paraspinal muscles with aging in healthy adults. **Med Sci Sport Exerc** 2017; 49(3): 595-601.

196. Soldath P, Wegener M, Sander B, Rosenberg T, Duno M, Wibrand F, Vissing J. Leber hereditary optic neuropathy due to a new *ND1* mutation. **Ophthalmic Genet** 2017; 38(5): 480-485.

197. Andersen G, Dahlqvist JR, Vissing CR, Heje K, Thomsen C, Vissing J. MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients. J Neurol 2017; 264(3): 438-447.

198. Andersen G, Løkken N, Vissing J. Aerobic training in myotonia congenita: effect on myotonia and fitness. **Muscle Nerve** 2017; 56(4): 696-699.

199. Prahm KP, Rasmussen UF, Vissing J. Human growth hormone stabilizes walking and improves strength in a patient with dominantly inherited calpainopathy. **Neuromuscul Disord** 2017: 27(4); 358-362.

200. Voermans NC, Preisler N, Madsen KL, Janssen MC, Kusters B, Abu Bakar N, Conte F, Lamberti VM, Nusman F, van Engelen BG, van Scherpenzeel M, Vissing J, Lefeber DJ. PGM1 deficiency: Substrate use during exercise and effect of treatment with galactose. **Neuromuscul Disord** 2017: 27(4); 370-376.

201. Witting N, Werlauff U, Duno M, Vissing J. Phenotypes, genotypes, and prevalence of congenital myopathies older than 5 years in Denmark. **Neurol Genet** 2017; 3(2): e140. doi: 10.1212/NXG.0000000000000140.

202. Knak KL, Andersen LK, Witting N, Vissing J. Reliability of the 2- and 6-minute walk tests in neuromuscular diseases. **J Rehabil Med** 2017: 49; 362-366.

203. Krag T, Ruiz CR, Vissing J. Glycogen synthesis in glycogenin 1 deficient patients; a role for glycogenin 2 in muscle. **J Clin Endo Metab** 2017: 102(8): 2690-2700.

204. Soldath P, Madsen KL, Buch AE, Duno M, Wibrand F, Vissing J. Pure exercise intolerance and ophthalmoplegia associated with the m.12,294G>A mutation in the MT-TL2 gene: a case report. **BMC Musculoskelet Disord** 2017 Oct 19; 18(1): 419. doi: 10.1186/s12891-017-1781-0.

205. Andersen G, Heje K, Buch AE, Vissing J. High-intensity interval training in facioscapulohumeral muscular dystrophy type 1: a randomized clinical trial. **J Neurol** 2017: 264(6): 1099-1106.

206. Preisler N, Laforêt P, Madsen KL, Husu E, Vissing C, Hedermann G, Galbo H, Lindberg C, Vissing J. Skeletal muscle metabolism during prolonged exercise in Pompe disease. **Endocr Connect** 2017; 6(6): 384-394.

207. Gaist D, Mogensen J, Pedersen EG, Schrøder HD, Vissing J, Andersen H, Hertz JM. DOK7 congenital myasthenia may be associated with severe mitral valve insufficiency. **J Neurol Sci** 2017; 379: 217-218.

208. Langdahl JH, Frederiksen AL, Hansen SJ, Andersen PH, Yderstraede KB, Dunø M, Vissing J, Frost M. Mitochondrial point mutation m.3243A>G associates with lower bone mineral density, thinner cortices and reduced bone strength. A case-control study. **J Bone Miner Res** 2017; 32(10): 2041-2048.

209. Jeppesen TD, Al-Hashimi N, Duno M, Wibrand F, Andersen G, Vissing J. Mitochondrial DNA mutation load in a family with the m.8344A>G point mutation and lipomas: A case study. Clin Case Rep 2017; 5(12): 2034-2039.

210. Stemmerik MG, Madsen KL, Laforêt P, Buch AE, Vissing J. Muscle glycogen synthesis and breakdown are both impaired in glycogenin-1 deficiency. **Neurology** 2017; 89(24): 2491-2494.

211. Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza, R; REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. **Lancet Neurol** 2017; 16(12):976-986.

212. Andersen G, Hedermann G, Witting N, Duno M, Andersen H, Vissing J. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. **Brain** 2017; 140(9): 2295–2305.

213. Ben Yaou R, Hubert A, Nelson I, Dahlqvist JR, Gaist D, Streichenberger N, Beuvin M, Krahn M, Petiot P, Parisot F, Michel F, Malfatti E, Romero N, Carlier RY, Eymard B, Labrune P, Duno M, Krag T, Cerino M, Bartoli M, Bonne G, Vissing J, Laforet P, Petit FM. Clinical heterogeneity and phenotype/genotype findings in 5 families with *GYG1* deficiency. **Neurol Genet** 2017 Dec 18;3(6):e208. doi: 10.1212/NXG.0000000000000208. eCollection 2017 Dec.

214. Preisler N, Cohen J, Vissing CR, Madsen KL, Heinicke K, Sharp LJ, Phillips L, Romain N, Park SY, Newby M, Wyrick P, Mancias P, Galbo H, Vissing J, Haller RG. Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency. **Mol Genet Metab** 2017; 122(3): 117-121.

215. Knak KL, Andersen LK, Vissing J. Aerobic anti-gravity exercise in patients with Charcot-Marie-Tooth disease types 1A and X: A pilot study. **Brain Behav** 2017 Nov 2;7(12):e00794. doi: 10.1002/brb3.794. eCollection 2017 Dec.

216. Knak KL, Andersen LK, Witting N, Vissing J. The 2- and 6-minute walk tests in neuromuscular diseases: Effect of heart rate correction on the learning effect. **Int J Phys Med Rehab** 2017, 5:4 DOI: 10.4172/2329-9096.1000415

217. Hansen JS, Pedersen EG, Gaist D, Bach FW, Vilholm OJ, Sandal B, Weitemeyer L, Nielsen K, Schlesinger FE, Preisler N, Vissing J, Andersen H. Screening for late-onset Pompe disease in western Denmark. **Acta Scand Neurol** 2018; 137(1): 85-90.

218. Tasca G, Monforte M, Díaz-Manera J, Brisca G, Semplicini C, D'Amico A, Fattori F, Pichiecchio A, Berardinelli A, Maggi L, Maccagnano E, Løkken N, Marini-Bettolo C, Munell F, Sanchez A, Alshaikh N, Voermans NC, Dastgir J, Vlodavets D, Haberlová J, Magnano G, Walter MC, Quijano-Roy S, Carlier RY, van Engelen BGM, Vissing J, Straub V, Bönnemann C, Mercuri E, Muntoni F, Pegoraro E, Bertini E, Udd B, Ricci E, Bruno C. MRI in sarcoglycanopathies: a large international cohort study. **J Neurol Neurosurg Psychiatry** 2018; 89(1): 72-77.

219. Markvardsen LH, Overgaard K, Heje K, Sindrup SH, Christiansen I, Vissing J, Andersen H. Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. **Muscle Nerve** 2018; 57(1): 70-76.

220. Østergaard ST, Johnson K, Stojkovic T, Krag T, De Ridder W, De Jonghe P, Baets J, Claeys KG, Fernández-Torrón R, Topf A, Colomer J, Nafissi S, Jamal-Omidi S, Bouchet-Seraphin C, Leturcq F, MacArthur DG, Lek M, Xu L, Nelson I, Straub V, Vissing J. Limb girdle muscular dystrophy due to mutations in *POMT2*. **J Neurol Neurosurg Psychiatry** 2018; 89(5): 506-512.

221. Nielsen TL, Pinós T, Brull A, Vissing J, Krag TO. Exercising with blocked muscle glycogenolysis: Adaptation in the McArdle mouse. **Mol Genet Metab** 2018; 123: 21-27.

222. Witting N, Laforêt P, Voerman NC, Roux-Buisson N, Bompaire F, Rendu J, Duno M, Feillet F, Kamsteeg EJ, Poulsen NS, Dahlqvist JR, Romero NB, Fauré J, Vissing J, Behin A. Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome. **Acta Neurol Scand** 2018; 137(5): 452-461.

223. Hedermann G, Dahlqvist JR, Løkken N, Vissing CR, Knak KL, Andersen LK, Thomsen C, Vissing J. Progressive fat replacement of muscle contributes to the disease mechanism of patients with single, large-scale deletions of mitochondrial DNA. **Neuromuscul Disord** 2018; 28(5): 408-413.

224. Langdahl JH, Larsen M, Frost M, Andersen PH, Yderstraede KB, Vissing J, Dunø M, Thomassen M, Frederiksen AL. Leucocytes mutation load declines with age in carriers of the m.3243A>G mutation. A 10-year prospective cohort. **Clin Genet** 2018; 93(4): 925-928.

225. Witting N, Krag T, Werlauff U, Duno M, Oestergaard ST, Dahlqvist JR, Vissing J. Collagen XII myopathy with rectus femoris atrophy and collagen XII retention in fibroblasts. **Muscle Nerve** 2018; 57(6): 1026-1030.

226. Lindberg U, Kruuse C, Witting N, Jørgensen SL, Vissing J, Rostrup E, Larsson HBW. Altered somatosensory neurovascular response in patients with Becker muscular dystrophy. **Brain Behav** 2018 Jun; e00985. doi.org 10.1002/brb3.985.

227. Oates E, Jones K, Donkervoort S, Charlton A, Brammah S, Smith JE 3rd, Ware J,S Yau KS, Swanson LC, Whiffin N, Peduto AJ, Bournazos A, Waddell LB, Farrar MA, Sampaio HA, Teoh HL, Lamont PJ, Mowat D, Fitzsimons RB, Corbett AJ, Ryan MM, O'Grady GL, Sandaradura SA, Ghaoui R,

Joshi HB, Marshall JL, Nolan MA, Kaur S, Punetha J, Töpf A, Harris E, Bakshi M, Genetti CA, Marttila M, Werlauff U, Streichenberger N, Pestronk A, Mazanti I, Pinner JR, Vuillerot C, Grosmann C, Camacho A, Mohassel P, Leach ME, Foley AR, Bharucha-Goeber D, Collins J, Connolly AM, Gilbreath HR, Iannaccone ST, Castro D, Cummings BB, Webster RI, Lazaro L, Vissing J, Coppens S, Deconinck N, Luk HM, Thomas NH, Foulds NC, Illingworth MA, Ellard S, McLean CA, Phadke R, Ravenscroft G, Witting N, Hackman P, Richard I, Cooper ST, Kamsteeg EJ, Hoffman EP, Bushby K, Straub V, Udd B, Ferreiro A, North KN, Clarke NF, Lek M, Beggs AH, Bonnemann CG, MacArthur DG, Granzier H, Davis MR, Laing, NG. Congenital titinopathy: Comprehensive characterization and pathogenic insights. **Ann Neurol** 2018; 83(6): 1105-1124.

228. Vissing J, O'Brien F, Wang JJ, Howard JF Jr. Correlation between MG-ADL and QMG assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 REGAIN study. **Muscle Nerve** 2018; 58(2): E21-E22.

229. Bakar, NA, Voermans NC, Marquardt T, Thiel C, Janssen MCH, Hansikova H, Crushell E, Sykut-Cegielska J, Bowling F, Mørkrid L, Vissing J, Morava E, Scherpenzeel Mv, Lefeber DJ. Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring in phosphoglucomutase-I deficiency. **Transl Res** 2018; 199: 62-76.

230. Andersen AG, Fornander F, Schrøder HD, Krag T, Straub V, Duno M, Vissing J. *BAG3* myopathy is not always associated with cardiomyopathy. **Neuromuscul Disord** 2018; 28(9): 798-801.

231. Borch JS, Eisum AV, Krag T, Vissing J. Expanding the phenotype of Filamin C-related myofibrillar myopathy. **Clin Neurol Neurosurg** 2018; 176: 30-33.

232. Sloth, CK, Denti F, Schmitt N, Bentzen BH, Fagerberg C, Vissing J, Gaist D. Homozygosity for *SCN4A* Arg1142Gln causes congenital myopathy with variable disease expression. **Neurol Genet** 2018 Sep 19;4(5):e267. doi: 10.1212/NXG.0000000000000267. eCollection 2018 Oct.

233. Johnson K, Bertoli M, Phillips L, Töpf A, Van den Bergh P, Vissing J, Witting N, Nafissi S, Jamal-Omidi S, Łusakowska A, Kostera-Pruszczyk A, Potulska-Chromik A, Deconinck N, Wallgren-Patterson C, Strang-Karlsson S, Colomer J, Claeys KG, De Ridder W, Baets J, von der Hagen M, Fernández-Torrón R, Zulaica Ijurco M, Espinal Valencia JB, Hahn A, Durmus H, Willis T, Xu L, Valkanas E, Mullen TE, Lek M, MacArthur DG, Straub V. Detection of variants in dystroglycanopathy-associated genes through the application of targeted whole exome sequencing analysis to a large cohort of patients with unexplained limb-girdle muscle weakness. **Skeletal Muscl** 2018 Jul 30;8(1):23. doi: 10.1186/s13395-018-0170-1.

234. Grunseich C, Miller R, Swan T, Glass DJ, Mouelhi ME, Fornaro M, Petricoul O, Vostiar I, Roubenoff R, Meriggioli MN, Kokkinis A, Guber RD, Budron MS, Vissing J, Soraru G, Mozaffar T, Ludolph A, Kissel JT, Fischbeck KH; BVS857 Study Group. Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. **Lancet Neurol** 2018; 17(12): 1043-1052.

235. Madsen KL, Preisler N, Rasmussen J, Hedermann G, Olesen JH, Lund AM, Vissing J. L-carnitine improves skeletal muscle fat oxidation in primary carnitine deficiency. **J Clin Endocrinol Metab** 2018; 103(12): 4580-4588.

236. Dahlqvist JR, Fornander F, de Stricker Borch J, Oestergaard ST, Poulsen NS, Vissing J. Disease progression and outcome measures in spinobulbar muscular atrophy. **Ann Neurol** 2018; 84(5): 754-765.

237. Vissing J, Akman HO, Aasly J, Kahler SG, Bacino CA, DiMauro S, Haller RG. Level of residual enzyme activity modulates the phenotype in phosphoglycerate kinase deficiency. **Neurology** 2018; 91(11): e1077-e1082.

238. Alonso-Jiménez A, Kroon RHMJM, Alejaldre-Monforte A, Núñez-Peralta C, Horlings CGC, van Engelen BGM, Olivé M, González L, Verges-Gil E, Paradas C, Márquez C, Garibaldi M, Gallano P, Rodriguez MJ, Gonzalez-Quereda L, Dominguez-Gonzalez C, Vissing J, Fornander F, Eisum AV, García-Sobrino T, Pardo J, García-Figueiras R, Muelas N, Vilchez JJ, Kapetanovic S, Tasca G, Monforte M, Ricci E, Gomez MT, Bevilacqua JA, Diaz-Jara J, Zamorano II, Carlier RY, Laforet P, Pelayo-Negro A, Ramos-Fransi A, Martínez A, Marini-Bettolo C, Straub V, Gutiérrez G, Martín MA, Morís G, Fernández-Torrón R, Lopez De Munaín A, Cortes-Vicente E, Querol L, Rojas-García R, Illa I, Diaz-Manera J. Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy patients. **J Neurol Neurosurg Psychiatry** 2019; 90(5): 576-585.

239. Dahlqvist JR, Oestergaard ST, Poulsen NS, Thomsen C, Vissing J. Refining the spinobulbar muscular atrophy phenotype by quantitative MRI and clinical assessments. **Neurology** 2019; 92(6): e548-e559.

240. Poulsen NS, Dahlqvist JR, Løkken N, Hedermann G, Thomsen C, Vissing J. Muscle contractility of leg muscles in patients with mitochondrial myopathy. **Mitochondrion** 2019; 46: 221-227.

241. Vaeth S, Christensen R, Dunø M, Lildballe DL, Thorsen K, Vissing J, Svenstrup K, Hertz JM, Andersen H, Jensen UB. Genetic analysis of Charcot-Marie-Tooth Disease in Denmark and the implementation of a next generation sequencing platform. **Eur J Med Genet** 2019; 62(1): 1-8.

242. **Vissing J. Paternal comeback in mitochondrial DNA inheritance. Proc Natl Acad Sci U S A** 2019; 16(5): 1475-1476.

243. Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Laforet P, Mengel KE, Pestronk A, Pouget J, Schoser B, Straub V, Trivedi J, Van Damme P, Vissing J, Young P, Kacena K, Shafi R, Thurberg BL, Culm-Merdek K, van der Ploeg AT; NEO1 Investigator Group. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. **Neuromuscul Disord** 2019; 29(3): 167-186.

244. Markvardsen LK, Carstens AR, Knak KL, Overgaard K, Vissing J, Andersen H. Muscle strength and aerobic capacity in patients with CIDP one year after participation in an exercise trial. **J Neuromuscul Dis** 2019; 6(1): 93-97.

245. Madsen KL, Preisler N, Buch AE, Stemmerik MP, Laforêt P, Vissing J. Impaired fat oxidation during exercise in multiple acyl-CoA dehydrogenase deficiency. **JIMD Rep** 2019; 46(1): 79-84.

246. Real-Martinez A, Brull A, Huerta J, Tarrasó G, Lucia A, Martin MA, Arenas J, Andreu AL, Nogales-Gadea G, Vissing J, Krag TO, de Luna N, Pinós T. Low survival rate and muscle fiber-dependent aging effects in the McArdle disease mouse model. **Sci Rep** 2019 Mar 26;9(1):5116. doi: 10.1038/s41598-019-41414-8.

247. Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casanovas C, De Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; REGAIN Study Group. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. **Muscle Nerve** 2019; 60(1): 14-24.

248. Dahlqvist JR, Andersen G, Khawajazada T, Vissing C, Thomsen C, Vissing J. Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy. **J Neurol** 2019; 266(5): 1127-1135.

249. Petri H, Wahbi K, Witting N, Køber L, Bundgaard H, Kamoun E, Vellieux G, Stojkovic T, Béhin A, Laforêt P, Vissing J. Congenital myopathies are mainly associated with a mild cardiac phenotype. **J Neurol** 2019; 266(6):1367-1375.

250. Fritzen AM, Thøgersen FB, Thybo K, Vissing CR, Krag TO, Ruiz-Ruiz C, Risom L, Wibrand F, Høeg LD, Kiens B, Duno M, Vissing J, Jeppesen TD. Adaptations in mitochondrial enzymatic activity occurs independent of genomic dosage in response to aerobic exercise training and deconditioning in human skeletal muscle. **Cells** 2019; Mar 12; 8(3): E237; doi:10.3390/cells8030237.

251. Dahlqvist JR, Oestergaard ST, Poulsen NS, Knak KL; Thomsen C, Vissing J. Muscle contractility in spinobulbar muscular atrophy. **Sci Rep** 2019 Mar 18;9(1):4680. doi: 10.1038/s41598-019-41240-y.

252. Murphy AP, Morrow J, Dahlqvist JR, Stojkovic T, Willis TA, Sinclair CDJ, Wastling S, Yousry T, Hanna MS, James M, Mayhew A, Eagle M, Lee LE, Hogrel J-Y, Thornton JS, Carlier PG, Vissing J, Hollingsworth KG, Straub V. Natural history of LGMD R9 over 6 years: searching for trial endpoints. **Ann Clin Transl Neuro** 2019; 16 (6): 1033-1045.

253. Bachmann C, Noreen F, Voermans NC, Schär PL, Vissing J, Fock JM, Bulk S, Kusters B, Moore SA, Beggs AH, Mathews KD, Meyer M, Genetti CA, Meola G, Cardani R, Mathews E, Jungbluth H, Muntoni F, Zorzato F, Treves S. Aberrant regulation of epigenetic modifiers contributes to the pathogenesis in patients with selenoprotein N-related myopathies. **Hum Mutat** 2019; 40(7): 962-974

254. Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group. Eculizumab improves fatigue in refractory generalized myasthenia gravis. **Qual Life Res** 2019; 28(8): 2247-2254.

255. Heje K, Andersen G, Buch A, Andersen H, Vissing J. High-intensity training in patients with spinal and bulbar muscular atrophy. **J Neurol** 2019; 266(7): 1693-1697.

256. Madsen KL, Stemmerik MG, Buch AE, Poulsen NS, Lund AM, Vissing J. Impaired fat oxidation during exercise in Long-Chain Acyl-CoA Dehydrogenase Deficiency patients and effect of IV-glucose. **J Clin Endocrinol Metab** 2019; 104(9): 3610-3613.

257. Hanna NG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Auberson LZ, Wu M, de Vera A, Papanicolaou DA, Amato AA; RESILIENT Study Group. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. **Lancet Neurol** 2019; 18(9): 834-844.

258. Vissing CR, Hedermann G, Vissing J. Moderate-intensity aerobic exercise improves physical fitness in Bethlem myopathy. **Muscle Nerve** 2019; 60(2): 183-188.

259. Raaschou-Pedersen D, Madsen KL, Stemmerik MG, Eisum AV, Straub V, Vissing J. Fat oxidation is impaired during exercise in Lipin-1 deficiency. **Neurology** 2019; 93(15): e1433-e1438.

260. Hoei-Hansen CE, Scheie D, Lund EL, Kondziella D, Vissing J, Christiansen I. Fatal kakeksi ved mitokondriel neurogastrointestinal encefalomyopati (Fatal cachexia caused by mitochondrial neuro-gastro-intestinal encephalomyopathy). **Ugeskr Laeger** 2019; 181(24): pii: V01190070.

261. Langdahl JH, Frederiksen AL, Vissing J, Nielsen MF, Yderstræde KB, Andersen PH. Mitochondrial mutation m.3243A>G associates with insulin resistance in non-diabetic carriers. **Endocr Connect** 2019; 8(7): 829-837.

262. Ross JA, Levy Y, Ripolone M, Kolb JS, Turmaine M, Holt M, Lindqvist J, Claeys KG, Weis J, Monforte M, Tasca G, Moggio M, Figeac N, Zammit PS, Jungbluth H, Fiorillo C, Vissing J, Witting N, Granzier H, Zanoteli E, Hardeman EC, Wallgren-Pettersson C, Ochala J. Impairments in contractility and cytoskeletal organisation cause nuclear defects in nemaline myopathy. **Acta Neuropathol** 2019; 138(3): 477-495.

263. Vissing J, Johnson K, Töpf A, Nafissi S, Díaz-Manera J, French VM, Schindler RF, Sarathchandra P, Løkken N, Rinné S, Freund M, Decher N, Müller T, Duno M, Krag T, Brand T, Straub V. POPDC3 gene variants associate with a new form of limb girdle muscular dystrophy. **Ann Neurol** 2019; 86(6): 832-843.

264. Madsen KL, Laforêt P, Buch AE, Stemmerik MG, Ottolenghi C, Hatem SN, Raaschou-Pedersen DT, Poulsen NS, Atencio M, Luton MP, Ceccaldi A, Haller RG, Quinlivan R, Mochel F, Vissing J. No effect of triheptanoin on exercise performance in McArdle disease. **Ann Clin Transl Neuro** 2019; 6(10): 1949-1960.

265. Laforêt P, Inoue M, Goillot E, Lefeuvre C, Cagin U, Streichenberger N, Leonard-Louis S, Brochier G, Madelaine A, Labasse C, Hedberg-Oldfors C, Krag T, Jauze L, Fabregue J, Labrune P, Milisenda J, Nadaj-Pakleza A, Sacconi S, Mingozzi F, Ronzitti G, Petit F, Schoser B, Oldfors A, Vissing

J, Romero NB, Nichino I, Malfatti E. Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment. **Acta Neuropathol Commun** 2019 Oct 28;7(1):167. doi: 10.1186/s40478-019-0815-2.

266. Donkervoort S, Sabouny R, Yun P, Gauquelin L, Chao KR, Hu Y, Töpf A, Mohassel P, Cummings BB, Kaur R, Saade D, Moore SA, Waddell LB, Farrar MA, Goodrich JK, Uapinyoying P, Chan SHS, Javed A, Leach ME, Karachunski P, Dalton J, Medne L, Harper A, Thompson C, Thiffault I, Specht S, Lamont RE, Saunders C, Racher H, Bernier FP, Mowat D, Witting N, Vissing J, Hanson R, Coffman KA, Hainlen M, Parboosingh JS, Carnevale A, Yoon G, Schnur RE; Care4Rare Canada Consortium, Boycott KM, Mah JK, Straub V, Foley AR, Innes AM, Bönnemann CG, Shutt TE. MSTO1 mutations cause mtDNA depletion, manifesting as muscular dystrophy with cerebellar involvement. **Acta Neuropathol** 2019; 138(6): 1013-1031.

267. Murai H, Uzawa A, Suzuki Y, Imai T, Shiraishi H, Suzuki H, Okumura M, O'Brien F, Wang JJ, Fujita KP, Utsugisawa K, REGAIN Study Group. Long-term Efficacy and Safety of Eculizumab in Japanese Patients with Generalized Myasthenia Gravis: A Subgroup Analysis of the REGAIN Open-Label Extension Study. **J Neurol Sci** 2019; 407: 116419. doi: 10.1016/j.jns.2019.08.004.

268. Markvardsen LK, Overgaard K, Vissing J, Andersen H. Exercise training in multifocal motor neuropathy - a case report study. **Clin Case Rep Rev** 2019; 5: doi: 10.15761/CCRR.1000460

269. Vissing CR, Dunø M, Wibrand F, Christensen M, Vissing J. Hydroxylated long-chain acylcarnitines are biomarkers of mitochondrial myopathy. **J Clin Endocrinol Metab** 2019; 104(12): 5968-5976.

270. Poulsen NS, Madsen KL, Hornshyld TM, Eisum AV, Fornander F, Buch AE, Stemmerik MG, Ruiz-Ruiz C, Krag TO, Vissing J. Growth and Differentiation Factor 15 as a biomarker for mitochondrial myopathy. **Mitochondrion** 2020; 50: 35-41.

271. Madsen KL, Buch AE, Cohen BH, Falk MJ, Goldsberry A, Goldstein A, Karaa A, Koenig MK, Muraresku CC, Meyer C, O'Grady M, Scaglia F, Shieh PB, Vockley J, Zolkipli-Cunningham Z, Haller RG, Vissing J. Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy (MOTOR Trial). **Neurology** 2020; 94(7): e687-e698.

272. Bryen SJ, Ewans L, Pinner J, MacLennan SC, Donkervoort S, Castro D, Töpf A, O'Grady G, Cummings B, Chao KR, Weisburd B, Francioli L, Faiz F, Bournazos AM, Hu Y, Malicki DM, Doyle H, Witting N, Vissing J, Claeys KG, Urankar K, Beleza-Meireles A, Baptista J, Ellard S, Majumdar A, Straub V, Bonnemann C, MacArthur DG, Davis MR, Cooper ST. Recurrent TTN metatranscript-only c.39974-11T>G splice variant associated with autosomal recessive arthrogryposis multiplex congenita and myopathy. **Hum Mutat** 2020; 41(2): 403-411.

273. Verdú-Díaz J, Alonso-Pérez J, Nuñez-Peralta C, Tasca G, Vissing J, Straub V, Fernández-Torrón R, Llauger J, Illa I, Díaz-Manera J. Accuracy of a machine learning muscle MRI-based tool for the diagnosis of muscular dystrophies. **Neurology** 2020; 94(10): e1094-e1102.

274. Barp A, Laforêt P, Bello L, Tasca G, Vissing J, Monforte M, Ricci E, Choumert A, Stojkovic T, Malfatti E, Pegoraro E, Semplicini C, Stramare R, Scheidegger O, Haberlova J, Straub V, Marini-Bettolo C, Løkken N, Diaz-Manera J, Urtizberea JA, Mercuri E, Kynčl M, Walter MC, Carlier RY. European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A). **J Neurol** 2020; 267(1): 45-56.

275. Tarrasó G, Real-Martinez A, Parés M, Romero-Cortadellas L, Puigros L, Moya L, de Luna N, Brull A, Martín MA, Arenas J, Lucía A, Andreu AL, Barquinero J, Vissing J, Krag TO, Pinós T. Absence of p.R50X *Pygm* read-through in McArdle disease cellular models. **Dis Model Mech** 2019 Dec 17. pii: dmm.043281. doi: 10.1242/dmm.043281. [Epub ahead of print]

276. Knak KL, Sheikh AM, Witting N, Vissing J. Intrarater reliability and validity of outcome measures in myotonic dystrophy type 1. **Neurology** 2020; 94(24): e2508-e2520.

277. Holm-Yildiz S, Witting N, Dahlqvist J, de Stricker Borch J, Solheim T, Fornander F, Eisum AS, Duno M, Soerensen T, Vissing J. Permanent muscle weakness in hypokalemic periodic paralysis. **Neurology** 2020; 95(4): e342-e352.

278. Knak KL, Sheikh AM, Witting N, Vissing J. Physical activity in myotonic dystrophy type 1. **J Neurol** 2020; 267(6): 1679-1686.

279. Løkken N, Hansen KK, Storgaard JH, Ørngreen MC, Quinlivan R, Vissing J. Titrating a modified ketogenic diet for patients with McArdle disease: a pilot study. **J Inherit Metab Dis** 2020 Feb 15. doi: 10.1002/jimd.12223. [Epub ahead of print]

280. Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group. `Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. **J Neurol** 2020; 267(7): 1991-2001.

281. Andersen AG, Ørngreen MC, Raaschou-Pedersen DET, Borch JS, Løkken N, Krag TO, Petersen MB, Vissing J. No effect of oral sucrose or IV glucose during exercise in phosphorylase b kinase deficiency. **Neuromuscul Disord** 2020; 30: 340-345.

282. Dahlqvist JR, Poulsen NS, Østergaard ST, Fornander F, de Stricker Borch J, Danielsen ER, Thomsen C, Vissing J. Evaluation of inflammatory lesions over 2 years in facioscapulohumeral muscular dystrophy. **Neurology** 2020 95(9): e1211-e1221.

283. Storgaard JH, Madsen KL, Løkken N, Vissing J, van Hall G, Lund AM, Ørngreen MC. Impaired lipolysis in propionic acidemia: A new metabolic myopathy? **JIMD Rep** 2020; 53(1): 16-21.

284. Soldath P, Lund A, Vissing J. Late-onset multiple acyl-CoA dehydrogenase deficiency: A Rare cause of acute liver failure. **Acta Myol** 2020; 39(1): 19-23.

285. Murphy LB, Schreiber-Katz O, Rafferty K, Robertson A, Topf A, Willis TA, Heidemann M, Thiele S, Bindoff L, Laurent JP, Lochmüller H, Mathews K, Mitchell C, Stevenson JH, Vissing J, Woods L, Walter MC, Straub V. Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9. **Ann Clin Transl Neurol** 2020; 7(5): 757-766.

286. Dahlqvist JR, Salim R, Thomsen C, Vissing J. A quantitative method to assess muscle edema using short TI inversion recovery MRI. **Sci Rep** 2020 Apr 29;10(1):7246. doi: 10.1038/s41598-020-64287-8.

287. Töpf A, Johnson K, Bates A, Phillips L, Chao KR, England EM, Laricchia KM, Mullen T, Valkanas E, Xu L, Bertoli M, Blain A, Casasús AB, Duff J, Mroczek M, Specht S, Lek M, Ensini M, MacArthur DG, MYO–SEQ consortium, Straub V. Sequential targeted exome sequencing of 1001 patients affected by unexplained limb–girdle weakness. **Genet Med** 2020; 22(9): 1478-1488.

288. Salim R, Dahlqvist JR, Khawajazada T, Kass K, Revsbech KL, de Stricker Borch J, Munawar Sheikh A, Vissing J. Characteristic muscle signatures assessed by quantitative MRI in patients with Bethlem myopathy. **J Neurol** 2020; 267(8): 2432-2442.

289. Scalco RS, Stemmerik M, Løkken N, Vissing CR, Madsen KL, Michalak Z, Pattni J, Godfrey R, Samandouras G, Bassett P, Holton JL, Krag T, Haller RG, Sewry C, Wigley R, Vissing J, Quinlivan R. Results of an open label feasibility study of Sodium Valproate in people with McArdle disease. **Neuromuscul Disord** 2020; 30(9): 734-741.

290. Echaniz-Laguna A, Lornage X, Laforêt P, Orngreen MC, Edelweiss E, Brochier G, Bui MT, Silva-Rojas R, Birck C, Lannes B, Romero NB, Vissing J, Laporte J, Böhm J. A new glycogen storage disease caused by a dominant *PYGM* mutation. **Ann Neurol** 2020; 88(2): 274-282.

291. Leermakers PA, Dybdahl KLT, Husted KS, Riisager A, de Paoli FV, Pinós T, Vissing J, Krag TOB, Pedersen TH. Depletion of ATP limits membrane excitability of skeletal muscle by increasing both ClC1-open probability and membrane conductance. **Front Neurol** 2020 Jun 19;11:541. doi: 10.3389/fneur.2020.00541. eCollection 2020.

292. Alonso-Pérez J, González-Quereda L, Bello L, Guglieri M, Straub V, Gallano P, Semplicini C, Pegoraro E, Zangaro V, Nascimento A, Ortez C, Comi GP, Dam LT, De Visser M, van der Kooi AJ, Garrido C, Santos M, Schara U, Gangfuß A, Løkken N, Storgaard JH, Vissing J, Schoser B, Dekomien G, Udd B, Palmio J, D'Amico A, Politano L, Nigro V, Bruno C, Panicucci C, Sarkozy A, Abdel-Mannan O, Alonso-Jimenez A, Claeys KG, Gomez-Andrés D, Munell F, Costa-Comellas L, Haberlová J, Rohlenová M, Elke V, De Bleecker JL, Dominguez-González C, Tasca G, Weiss C, Deconinck N, Fernández-Torrón R, López de Munain A, Camacho-Salas A, Melegh B, Hadzsiev K, Leonardis L, Koritnik B, Garibaldi M, de Leon-Hernández JC, Malfatti E, Fraga-Bau A, Richard I, Illa I, Díaz-Manera J. New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. **Brain** 2020; 143(9): 2696-2708.

293. Holm-Yildiz S, Krag T, Witting N, Duno M, Soerensen T, Vissing J. Vacuoles, often containing glycogen, are a consistent finding in hypokalemic periodic paralysis. **J Neuropathol Exp Neurol** 2020; 79(10): 1127-1129.

294. Vissing J, Dahlqvist JR, Roudaut C, Poupiot J, Richard I, Duno M, Krag T. A single c.1715G>C calpain 3 gene variant causes dominant calpainopathy with loss of calpain 3 expression and activity. **Hum Mut** 2020; 41(9): 1507-1513.

295. Eisum AV, Fornander F, Poulsen NS, Andersen AG, Dahlqvist J, Andersen LK, Witting N, Vissing J. Contractile properties are impaired in congenital myopathy. **Neuromuscul Disord** 2020; 30(8): 649-655.

296. Knak KL, Sheikh AM, Witting N, Vissing J. Responsiveness of outcome measures in myotonic dystrophy type 1. **Ann Clin Transl Neurol** 2020; 7(8): 1382-1391.

297. Pinós T, Andreu AL, Bruno C, Hadjigeorgiou GM, Haller RG, Laforêt P, Lucía A, Martín MA, Martinuzzi A, Navarro C, Oflazer P, Pouget J, Quinlivan R, Sacconi S, Scalco RS, Toscano A, Vissing J, Vorgerd M, Wakelin A, Martí R, EUROMAC Consortium. Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC Registry). **Orphanet J Rare Dis** 2020 Oct 15;15(1):187. doi: 10.1186/s13023-020-01455-z.

298. Fritzen AM, Thøgersen FD, Qadri KAN, Krag T, Sveen ML, Vissing J, Jeppesen TD. Preserved capacity for adaptations in strength and muscle regulatory factors in elderly in response to resistance exercise training and deconditioning. **J Clin Med** 2020; Jul 10;9(7):E2188, doi:10.3390/jcm9072188.

299. Giacomucci G, Monforte M, Diaz-Manera J, Mul K, Frenandez Torrón R, Maggi L, Marini Bettolo C, Dahlqvist JR, Haberlova J, Camaño P, Gros M, Tartaglione T, Cristiano L, Gerevini S, Calandra P, Deidda G, Giardina E, Sacconi S, Straub V, Vissing J, Van Engelen B, Ricci E, Tasca G. Deep phenotyping of facioscapulohumeral muscular dystrophy type 2 by magnetic resonance imaging. **Eur J Neurol** 2020; 27(12): 2604-2615.

300. Mantegazza R, O'Brien FL, Yountz M, Howard JF Jr; REGAIN study group. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. **Ann Clin Transl Neurol** 2020 Jul 22. doi: 10.1002/acn3.51121. Online ahead of print.

301. Rooks D, Swan T, Goswami B, Filosa LA, Bunte O, Panchaud N, Coleman LA, Miller RR, Garcia Garayoa E, Praestgaard J, Perry RG, Recknor C, Fogarty CM, Arai H, Chen LK, Hashimoto J, Chung YS, Vissing J, Laurent D, Petricoul O, Hemsley S, Lach-Trifilieff E, Papanicolaou DA, Roubenoff R. Bimagrumab and optimized standard of care for treatment of sarcopenia in community-dwelling older adults: A randomized clinical trial. *JAMA Netw Open* 2020;3(10): e2020836. doi:10.1001/jamanetworkopen. 2020.20836

302. Hildonen M, Knak KL, Dunø M, Vissing J, Tümer Z. Stable Longitudinal Methylation Levels at the CpG Sites Flanking the CTG Repeat of *DMPK* in Patients with Myotonic Dystrophy Type 1. **Genes (Basel)** 2020 Aug 13;11(8):E936. doi: 10.3390/genes11080936.

303. Raz V, Kroon RHMJM, Mei H, Riaz M, Buermans H, Lassche S, Horlings C, Swart B, Kalf J, Harish P, Vissing J, Kielbasa S, van Engelen BGM. Age-Associated Salivary MicroRNA Biomarkers for Oculopharyngeal Muscular Dystrophy. **Int J Mol Sci** 2020 Aug 22;21(17):E6059. doi: 10.3390/ijms21176059.

304. Jeppesen TD, Duno M, Vissing J. Mutation load of single, large-scale deletions of mtDNA in mitotic and post-mitotic tissues. **Front Genet** 2020 Oct 2;11:547638. doi: 10.3389/fgene.2020.547638. eCollection 2020.

305. Muppidi S, Guptill JT, Jacob S, Li Y, Farrugia ME, Guidon AC, Tavee JO, Kaminski H, Howard JF Jr, Cutter GR, Wiendl H, Maas MB, Illa I, Mantegazza R, Murai H, Utsugisawa K, Nowak RJ, Tyagi A, Sousa AP, Amato AA, Pinto A, Roy B, Carmichael C, Dodig D, Burke G, Lee I, Caress J, Pritchard J, Vissing J, Best K, Ramezani M, Maas M, Hehir MK, Kaku M, Esquivel NJ, Gallagher P, Maddison P, Ambrose PA, Campo RVD, Saba S, Nafissi S, Itoyama S, Viegas SV, Marshall V, Li YL. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). **Lancet Neurol** 2020; 19(12): 970-971

306. Brown SC, Fernandez-Fuente M, Muntoni F, Vissing J. Phenotypic spectrum of α-dystroglycanopathies associated with the c.919T>A variant in the *FKRP* gene in humans and mice. **J Neuropathol Exp Neurol** 2020; 79(12): 1257-1264.

307. Fritzen AM, Andersen SP, Qadri KAN, Thøgersen FD, Krag T, Ørngren MC, Vissing J, Jeppesen TD. Effect of aerobic exercise training and deconditioning on oxidative capacity and muscle mitochondrial enzyme machinery in young and elderly individuals. **J Clin Med** 2020 Sep 26;9(10):E3113. doi: 10.3390/jcm9103113.

308. Scalco RS, Lucia A, Santalla A, Martinuzzi A, Vavla M, Reni G, Toscano A, Musumeci O, Voermans NC, Kouwenberg CV, Laforêt P, San-Millán B, Vieitez I, Siciliano G, Kühnle E, Trost R, Sacconi S, Stemmerik MG, Durmus H, Kierdaszuk B, Wakelin A, Andreu AL, Pinós T, Marti R, Quinlivan R, Vissing J; EUROMAC Consortium. Data from the European registry for patients with McArdle disease and muscle glycogenosis (EUROMAC). **Orphanet J Rare Dis** 2020 Nov 24;15(1):330. doi: 10.1186/s13023-020-01562-x.

309. Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, Kiessling P, Woltering F, Griffin L, Van den Bergh P; MG0002 Investigators. Efficacy and safety of rozanolixizumab in moderate-to-severe generalised myasthenia gravis: A phase 2 RCT. **Neurology** 2021; 96(6): e853-e865.

310. Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Auberson LZ; RESILIENT Study Extension Group. Efficacy and safety of bimagrumab in sporadic inclusion body myositis: Long-term extension of RESILIENT. **Neurology** 2021; 96(12): e1595-e1607

311. Sheikh AM, Rudolf K, Witting N, Vissing J. Quantitative muscle MRI as outcome measure in patients with Becker muscular dystrophy - a 1-year follow-up study. **Front Neurol** 2021 Jan 5; 11:613489. doi: 10.3389/fneur.2020.613489. eCollection 2020.

312. Andersen LK, Witting N, Vissing J. Effect of rhythmic auditory stimulation on walking speed in patients with myasthenia gravis. **Eur J Physiotherp**

313. Krett B, Straub V, Vissing J. Episodic hyperCKemia may be a feature of α-methylacyl-CoA racemase deficiency. **Eur J Neurol** 2021; 28(2): 729-731.

314. Werlauff U, Hansen PD, Witting N, Vissing J. Progression or Not - A Small Natural History Study of Genetical Confirmed Congenital Myopathies. **J Neuromuscl Disord** 2021; 8(4): 647-655.

315. Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O'Brien FL, Booth HDE, Howard JF Jr; REGAIN Study Group. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. **Neurology** 2021; 96(4): e610-e618.

316. Vaeggemose M, Mencagli RA, Hansen JS, Dräger B, Ringgaard S, Vissing J, Andersen H. Function, structure and quality of striated muscles in the lower extremities in patients with late onset Pompe Disease – an MRI study. **PeerJ** 2021 May 6;9:e10928. doi: 10.7717/peerj.10928. eCollection 2021.

317. Sheikh AM, Rudolf K, de Stricker Borch J, Khawajazada T, Witting N, Vissing J. Patients with Becker muscular dystrophy have severe paraspinal muscle involvement. **Front Neurol** 2021 May 21;12:613483. doi: 10.3389/fneur.2021.613483. eCollection 2021.

318. Løkken N, Khawajazada T, Storgaard JH, Raaschou-Pedersen D, Christensen ME, Hornsyld TM, Krag T, Ørngreen MC, Vissing J. No effect of Resveratrol in patients with mitochondrial myopathy: a cross-over randomized controlled trial. **J Inherit Metab Dis** 2021; 44(5): 1186-1198.

319. Buch AE, Musumeci O, Wigley R, Stemmerik MPG, Eisum AV, Madsen KL, Preisler N, Hilton-Jones D, Quinlivan R, Toscano A, Vissing J. Energy metabolism during exercise in patients with β-enolase deficiency (GSDXIII). **JIMD Rep** 2021; 61(1): 60-66.

320. Andersen LK, Aadahl M, Vissing J. Fatigue, physical activity and associated factors in 779 patients with myasthenia Gravis. **Neuromuscl Disord** 2021; 31(8): 716-725.

321. Krag TO, Holm-Yildiz S, Witting N, Vissing J. Autophagy is affected in patients with hypokalemic periodic paralysis: an involvement in vacuolar myopathy? **Acta Neuropathol Commun** 2021 Jun 13; 9(1): 109. doi: 10.1186/s40478-021-01212-8.

322. Khawajazada T, Kass K, Rudolf K, de Stricker Borch J, Sheikh AM, Witting N, Vissing J. Muscle involvement assessed by quantitative magnetic resonance imaging in patients with anoctamin 5 deficiency. **Eur J Neurol** 2021; 28(9): 3121-3132.

323. Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. **Lancet Neurol** 2021; 20(7): 526-536.

324. Solheim TÅ, Fornander F, Raja AA, Møgelvang R, Poulsen NS, Dunø M, Bundgaard H, Vissing J. Cardiac involvement in women with pathogenic dystrophin gene variants. **Front Neurol** 2021 Jul 27;12:707838. doi: 10.3389/fneur.2021.707838. eCollection 2021.

325. Stemmerik MG, Borch JS, Dunø M, Krag T, Vissing J. Myopathy can be a key phenotype of membrin (GOSR2) deficiency. **Hum Mutat** 2021; 42(9):1101-1106.

326. Løkken N, Vinther Skriver S, Khawajazada T, Helbo Storgaard J, Vissing J. Plasma lactate responses during and after submaximal handgrip exercise are not diagnostically helpful in mitochondrial myopathy. **Mitochondrion** 2021; 60: 21-26.

327. Fornander F, Solheim TÅ, Eisum AV, Poulsen NS, Andersen AG, Dahlqvist JR, Dunø M, Vissing J. **Quantitative muscle MRI and clinical findings in women with pathogenic dystrophin gene variants. Front Neurol** 2021 Sep 3;12:707837. doi: 10.3389/fneur.2021.707837. eCollection 2021.

328. Ørngreen MC, Andersen AG, Eisum AS, Hald EJ, Raaschou-Pedersen DE, Løkken N, Høi-Hansen CE, Vissing J, Born AP, van Hall G. Prolonged fasting induced hyperketosis, hypoglycaemia and impaired fat oxidation in child and adult patients with spinal muscular atrophy type II. **Acta Paediatr** 2021; 110(12): 3367-3375.

329. Holm-Yildiz S, Witting N, de Stricker Borch J, Kass K, Khawajazada T, Krag T, Vissing J. Muscle biopsy and MRI findings in ANO5-related myopathy. **Muscle Nerve** 2021; 64(6): 743-748.

330. Kjeld T, Isbrand AB, Linnet K, Zerahn B, Højbjerg J, Hansen EG, Gormsen LC, Bejder J, Krag T, Vissing J, Bøtker HE, Arendrup HC. Extreme Hypoxia Causing Brady-Arrythmias During Apnea in Elite Breath-Hold Divers. **Front Physiol** 2021 Dec 3;12:712573. doi: 10.3389/fphys.2021.712573. eCollection 2021.

331. Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F; REGAIN Study Group. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. **Muscle Nerve** 2021; 64(6): 662-669.

332. Revsbech KL, Rudolf K, Sheikh AM, Khawajazada T, de Stricker Borch J, Dahlqvist JR, Løkken N, Witting N, Vissing J. Axial muscle involvement in patients with limb girdle muscular dystrophy type R9. **Muscle Nerve** 2022; 65(4):405-414

333. Storgaard JH, Løkken N, Madsen KL, Voermans NC, Laforêt P, Nadaj-Pakleza A, Tard C, van Hall G, Vissing J, Ørngreen MC. No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: a randomized clinical cross-over trial. **J Inherit Metab Dis** 2022 Jan 23. doi: 10.1002/jimd.12479. Online ahead of print.

334. Hoei-Hansen CE, Tygesen MLB, Dunø M, Vissing J, Ballegaard M, Born AP. Combined Muscle biopsy and comprehensive electrophysiology in general anaesthesia is valuable in diagnosis of neuromuscular disease in children. **Neuropediatrics** 2021 Mar 11. doi: 10.1055/s-0041-1726120. Online ahead of print.

335. Andersen LK, Jakobsson AS, Revsbech KL, Vissing J. Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. **J Neurol** 2021; Nov 21. doi: 10.1007/s00415-021-10902-1. Online ahead of print.

336. Gidaro T, Gasnier E, Annoussamy M, Vissing J, Attarian S, Mozaffar T, Iyadurai S, Wagner K, Vissière D, Walker G, Shukla SS, Servais L. Home-based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy. **Muscle Nerve** 2022; 65(2): 237-242.

337. Björkman K, Vissing J, Østergaard E, Bindoff LA, de Coo IFM, Engvall M, Hikmat O, Isohanni P, Kollberg G, Lindberg C, Majamaa K, Naess K, Uusima J, Tulinius M, Darin N. Phenotypic spectrum and clinical course of single large-scale mitochondrial DNA deletion disease in the paediatric population: a multicentre study. **J Med Genet** 2021 Dec 6: jmedgenet-2021-108006. doi: 10.1136/jmedgenet-2021-108006. Online ahead of print.

338. Quijano-Roy S, Haberlova J, Castiglioni C, Vissing J, Munell F, Rivier F, Stojkovic T, Malfatti E, Gómez García de la Banda M, Tasca G, Costa Comellas L, Benezit A, Amthor H, Dabaj I, Gontijo Camelo C, Laforêt P, Rendu J, Romero NB, Cavassa E, Fattori F, Beroud C, Zídková J, Leboucq N, Løkken N, Sanchez-Montañez Á, Ortega X, Kynčl M, Metay C, Gómez-Andrés D, Carlier RY. Diagnostic interest of Whole-Body MRI in early- and late-onset LAMA2 muscular dystrophies: A large international cohort. **J Neurol** 2022; 269(5): 2414-2429.

339. Kahr Andersen L, Vissing J. Habitual physical activity in patients with myasthenia gravis assessed by accelerometry and questionnaire. **J Neuromuscl Dis** 2022; 9(1): 161-169.

340. Basse AL, Agerholm M, Farup J, Dalbram E, Nielsen J, Ørtenblad N, Altıntaş A, Ehrlich AM, Krag T, Bruzzone S, Dall M, de Guia RM, Jensen JB, Møller AB, Kjær M, Barrès R, Vissing J, Larsen S, Jessen N, Treebak JT. Nampt controls skeletal muscle development by maintaining Ca^{2+} homeostasis and mitochondrial integrity. **Mol Metab** 2021 Jun 10:101271. doi: 10.1016/j.molmet.2021.101271. Online ahead of print.

341. Nielsen TL, Hornsyld TM, Pinós T, Brolin C, Vissing J, Krag TO. Growth factors do not improve muscle function in young and adult *mdx* mice. **Biomedicines** 2022; Jan 28;10(2):304. doi: 10.3390/biomedicines10020304.

342. Raaschou-Pedersen DE, Madsen KL, Løkken N, Storgaard JH, Quinlivan R, Laforêt P, Lund A, Van Hall G, Vissing J, Ørngreen MC. No effect of triheptanoin in patients with phosphofructokinase deficiency. **Neuromuscul Dis** 2022; 32(4):295-304.

343. Løkken N, Storgaard JH, Revsbech KL, Voermans NC, Van Hall G, Vissing J, Ørngreen MC. No effect of oral ketone ester supplementation on exercise capacity in patients with McArdle disease and healthy controls: a randomized placebo-controlled cross-over study. **J Inherit Metab Dis** 2022; 45(3): 502-516.

344. Witting N, Daugaard D, Prytz S, Biernat H, Diederichsen LP, Vissing J. Botulinum toxin treatment improves dysphagia in patients with oculopharyngeal muscular dystrophy and sporadic inclusion body myositis. **J Neurol** 2022 Mar 4. doi: 10.1007/s00415-022-11028-8. Online ahead of print.

345. Dimachkie MM, Barohn RJ, Byrne B, Goker-Alpan O, Kishnani PS, Ladha S, Laforêt P, Mengel KE, Loren DM, Pena LDM, Sacconi S, Straub V, Trivedi J, van Damme P, van der Ploeg AT, Vissing J,

Young P, Haack KA, Miossec P, Vitse O, Zhou T, Schoser B, on behalf of the NEO-EXT investigators. Long-term safety and efficacy of avalglucosidase alfa in late-onset Pompe disease in the NEO1 & NEO-EXT studies. **Neurology** In press

346. Bayat A, Krett B, Dunø M, Torring PM, Vissing, J. Novel truncating variants in *FGD1* detected in two Danish families with Aarskog-Scott syndrome and myopathic features. **Am J Med Genet A** 2022 Apr 7. doi: 10.1002/ajmg.a.62753. Online ahead of print.

347. Løkken N, Revsbech KL, Jacobsen LN, Martinuzzi A, Martin MA, Díaz-Manera J, Dominguez-Gonzalez C, Brondani G, Musumeci O, Granata F, Stefan C, Merino-Sanchez C, Nuñez C, Khawajazada T, Alonso-Pérez J, Toscano A, Vissing J. Muscle MRI in McArdle disease: a European multicenter observational study. **Neurology** In press

Medical dissertation (Doktordisputats)

Vissing J. Muscle reflex and central motor control of neuroendocrine activity, glucose homeostasis and circulation during exercise. **Acta Physiol Scand** 2000; 170 (suppl. 647): 1-26.

Review papers and book chapters

1. Galbo H, Sonne S, Vissing J, Kjær M, Mikines K, Richter EA. Lack of accuracy of fuel mobilization in exercise. I **Biochemical Aspects of Physical Exercise**, Benzi G, Packer L, Siliprandi N (red). Elsevier Science Publishers BV. 1986; 221-234.

2. Galbo H, Ploug T, Mikines KJ, Vinten J, Vissing J, Richter EA. The effect of insulin and contractions on glucose uptake in muscle. I **Advances in Myochemistry**, Benzi G (red). London: John Libbey Eurotext Ltd. 1987; 13-23.

3. Stallknecht B, Vissing J, Galbo H. Lactate production and clearance in exercise. Effects of training. **Scand J Med Sci Sports** 1998; 8: 127-131.

4. Vissing J. Disorders of of muscle glycogenolysis/glycolysis: Critical issues in diagnosis and management. I **Evaluation of Metabolic Myopathies**, Haller RG (red). Education Program Syllabus Vol. 7AS.001; American Academy of Neurology, 1999; 20-38.

5. Haller RG, Vissing J. Circulatory regulation in muscle disease. I **Exercise and Circulation in Health and Disease**, Saltin B, Boushel R, Secher N, Mitchell JH (red). Champaign, Illinois: Human Kinetics. 1999; 271-282.

6. Vissing J. Diagnostik af muskelsygdomme. **Ugeskr Læger** 2000; 162: 2173-2177.

7. Vissing J, Haller RG. Metabolic myopathies. I **Neuromuscular Disease: Expert Clinician's Views**, Pourmand R (red). Boston: Butterworth-Heinemann. 2001; Chapter 11: 393-410.

8. Vissing J. Exercise testing in muscle disease. I **Brain Disease: Therapeutic Strategies and Repair**, Abramsky O, Compston DAS, Miller A, Said G (red). London: Martin Dunitz Publishers. 2002; Chapter 41: 357-365.

9. Vissing J. Mitochondrial myopathies. I **Skeletal Muscle: Pathology, Diagnosis and Management of Disease**, Preedy VR, Peters TJ (red). London: Greenwich Medical Media Ltd. 2002; Chapter 14: 153-166.

10. Schwartz, M, Vissing J. New patterns of inheritance in mitochondrial disease. **Biochem Biophys Res Commun** 2003; 310: 247-251.

11. Vissing J, Soelberg Sørensen P. Muskelsygdomme. I **Klinisk Neurologi og Neurokirurgi**. 4. udgave. Kapitel 31. Paulson O, Gjerris F, Soelberg Sørensen P (red). FADL's Forlag, København. 2004; 593-608.

12. Vissing J, Skovby F. Nervesystemets arvelige stofskiftesygdomme. I **Klinisk Neurologi og Neurokirurgi**. 4. udgave. Kapitel 26. Paulson O, Gjerris F, Soelberg Sørensen P (red). FADL's Forlag, København. 2004; 527-536.

13. Vissing J, Bjerre P. Neurologi og Neurokirurgi. I **Basisbog i Medicin & Kirurgi**, 3. udgave. Schroeder TV, Schulze S, Hilsted J. Aldersville J (red). Munksgaard, København. 2004; 681-726.

14. Haller RG, Vissing J. Functional evaluation of metabolic myopathies. I **Myology: Basic and Clinical**, 3rd edition, Engel AG, Franzini-Armstrong C (red). McGraw-Hill Inc, New York. 2004; 665-679.

15. Vissing J. Muskelsygdomme. I **Neurologi og Neurorehabilitering**, 1. udgave. Wæhrens E, Winkel A, Gyring J. (red). Munksgaard, København. 2006; 163-169.

16. Chinnery P, Vissing J. Treating MNGIE: Is reducing blood nucleosides the first cure for a mitochondrial disorder? **Neurology** 2006; 67: 1330-1332.

17. Vissing J, Bjerre P. Neurologi og Neurokirurgi. I **Basisbog i Medicin & Kirurgi**, 4. udgave. Schroeder TV, Schulze S, Hilsted J. Gøtzsche L (red). Munksgaard, København. 2007; kapitel 20: 647-692.

18. Quinlivan R, Vissing J. 144th ENMC International Workshop: Outcome Measures in McArdle Disease, 29 September-1 November 2006, Naarden, the Netherlands. **Neuromuscul Disord** 2007; 17: 494-498.

19. Vissing J. Glycogen (Branching Enzyme Deficiency. I **Encyclopedia of Molecular Mechanisms of Disease.** Lang F (red). Springer-Verlag Berlin Heidelberg. 2009; Part 7: 727-728.

20. Waldemar G, Boysen GM, Høgenhaven H, Knudsen GM, Krarup C, Olesen J, Paulson OB, Sørensen PS, Vissing J. Neurologi. I **Medicinsk Kompendium** 17. udgave. Schaffalitzky de Muckadell OB, Haunsø S, Vilstrup H (red). Nyt Nordisk Forlag Arnold Busck, København. 2009; 2418-2623.

21. Vissing J. Myoglobinuria. I **International Neurology: A Clinical Approach**, 1st edition. Lisak RP, Truong DD, Carroll W, Bhidayasiri R (red). Blackwell Publishing, Oxford, United Kingdom. 2009; chapter 125: 477-479.

22. Vissing J, Di Donato S, Taroni F. Metabolic myopathies. I **Disorders of Voluntary Muscles**, 8th edition. Karpati G, Hilton-Jones D, Bushby K, Griggs RC (red). Cambridge University Press. UK. 2009; chapter 20: 390-407.

23. Haller, RG, Vissing, J. Muscle fatigue in metabolic myopathies. I **Human Muscle fatigue: In Sport, Exercise and Health**. Chapter 12. Williams C, Ratel S (red). Routledge, Taylor & Francis Group. London. 2009: 338-359.

24. Haller RG, Vissing J. Drilling for energy in mitochondrial disease. **Arch Neurol** 2009; 66: 931-932.

25. Skovby F, Vissing J. Arvelige neurometaboliske sygdomme. I **Klinisk Neurologi og Neurokirurgi**. 5. udgave. Kapitel 27. Paulson O, Gjerris F, Soelberg Sørensen P (red). FADL's Forlag, København. 2010; 555-564.

26. Vissing J, Paulson O. Defekter i den neuromuskulære transmission. I **Klinisk Neurologi og Neurokirurgi**. 5. udgave. Kapitel 31. Paulson O, Gjerris F, Soelberg Sørensen P (red). FADL's Forlag, København. 2010; 615-622.

27. Vissing J, Soelberg Sørensen P. Muskelsygdomme. I **Klinisk Neurologi og Neurokirurgi**. 5. udgave. Kapitel 32. Paulson O, Gjerris F, Soelberg Sørensen P (red). FADL's Forlag, København. 2010; 623-638.

28. Laforêt P, Vianey-Saban C, Vissing J. 162nd ENMC International Workshop: Disorders of muscle lipid metabolism in adults, 28-30 November 2008, Bussum, The Netherlands. **Neuromuscul Disord** 2010; 20: 283-289.

29. Quinlivan R, Vissing J, Hilton-Jones D, Buckley J. Physical training for McArdle disease. **Cochrane Database Syst Rev** 2011; 12: CD007931.

30. Angelini C, Federico A, Reichmann H, Lombes A, Vianey-Saban C, Chinnery P, Turnbull D, Vissing J. Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. **European Handbook of Neurological Management** Vol 1 (2nd ed), Gilhus NE, Barnes MP, Brainin M (red). Blackwell Publishing Ltd. 2011; Chapter 37: 501-511.

31. Andersen H, Bach F, Gaist D, Hansen K, Jakobsen J, Vissing J, Frost A, Gredal O, Rahbek J. Retningslinjer for Myastenibehandlingen i Danmark 2011. pp. 1-35. www.rcfm.dk/fileadmin/rcfm_filer/dokumenter/myasteniretningslinier4.pdf

32. Vissing J, Haller, RG. Mechanisms of exertional fatigue in muscle glycogenoses. **Neuromuscul Disord** 2012; Suppl 3: S168-S171.

33. Petri H, Vissing J, Witting N, Bundgaard H, Køber L. Cardiac manifestations of myotonic dystrophy type 1. **Int J Cardiol** 2012; 160(2): 82-88.

34. Jakobsen JK, Vissing J. Neuromuskulære sygdomme. I **Medicin**. Baslund B., Feldt-Rasmussen U, Kastrup J, Sørensen PS (red). FADL's Forlag. 2012: Kapitel 12, afsnit 13; 1099-1117.

35. Vissing J. Disorders of glycogen metabolism. I **Muscle Disease: Pathology and Genetics.** 2nd edition. Goebel HH, Sewry CA, Weller RO (red). John Wiley & Sons, Ltd. 2013; Chapter 28: 254-264.

36. Vissing J, van Engelen B. 160th ENMC International Workshop (First ENMC practical care workshop): Exercise training in patients with muscle diseases, Naarden, The Netherlands. **Neuromuscul Disord** 2013; 23: 182-187.

37. Vissing J, Lukacs Z, Straub V. Diagnosis of Pompe disease: Muscle biopsy vs blood-based assays. **JAMA Neurology** 2013; 70: 923-927.

38. Waldemar G, Ashina M, Christensen H, Høgenhaven H, Knudsen GM, Krarup C, Paulson OB, Sørensen PS, Vissing J, Østergaard K. Neurologi. I **Medicinsk Kompendium** 18. udgave. Schaffalitzky de Muckadell OB, Haunsø S, Vilstrup H (red). Nyt Nordisk Forlag Arnold Busck, København. 2013; Kapitel 56: 2341-2552. (ISBN 9878717042391)

39. Kyriakides T, Angelini C, Schaefer J, Mongini T, Siciliano G, Sacconi S, Joseph J, Burgunder JM, Bindoff LA, Vissing J, de Visser M, Hilton-Jones D. EFNS review on the role of muscle biopsy in the investigation of myalgia. **Eur J Neurol** 2013; 20(7): 997-1005.

40. Rose MR; ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. **Neuromuscul Disord** 2013; 23(12): 1044-1055.

41. Ørngreen MC, Vissing J. Metabolic myopathies. I **Neuromuscular disorders**, Hilton-Jones D, Turner M (red). Oxford University Press. Oxford. 2014; Chapter 29: 288-301.

42. Frederiksen AL, Nielsen MF, Yderstræde K, Vissing J. Det komplekse kliniske billede ved arvelige mitokondriesygdomme. **Ugeskr Læger** 2014; 176(38): 1779-1783.

43. Witting N, Vissing J. Pharmacologic treatment of Downstream of tyrosine kinase 7 congenital myasthenic syndrome. **JAMA Neurol** 2014; 71(3): 350-354.

44. Preisler N, Haller RG, Vissing J. Exercise in muscle glycogen storage diseases. **J Inherit Metab Dis** 2015; 38(3): 551-563.

45. Vissing J, Gaist D. Defekter i den neuromuskulære transmission. I **Klinisk Neurologi og Neurokirurgi**. 6. udgave. Kapitel 32. Paulson OB, Gjerris F, Sørensen PS (red). FADL's Forlag, København. 2015; 720-727.

46. Vissing J, Witting N. Muskelsygdomme. I **Klinisk Neurologi og Neurokirurgi**. 6. udgave. Kapitel 33. Paulson OB, Gjerris F, Sørensen Ps (red). FADL's Forlag, København. 2015; 728-747.

47. Skovby F, Vissing J. Arvelige neurometaboliske sygdomme. I **Klinisk Neurologi og Neurokirurgi**. 6. udgave. Kapitel 28. Paulson OB, Gjerris F, Sørensen PS (red). FADL's Forlag, København. 2015; 658-667.

48. Schoser B, Laforêt P, Kruijshaar ME, Toscano A, van Doorn PA, van der Ploeg AT; European Pompe Consortium (EPOC). 208th ENMC International Workshop: Formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26-28 September 2014. **Neuromuscul Disord** 2015; 25(8): 674-678.

49. Vissing J. Exercise intolerance and myoglobinuria. I **International Neurology: A Clinical Approach**, 2nd edition. Lisak RP, Truong DD, Carroll W, Bhidayasiri R (eds). John Wiley & Sons Ltd., United Kingdom. 2016; Chapter 126: 516-519.

50. Dahlqvist JR, Vissing J. Exercise therapy in spinobulbar muscular atrophy and other neuromuscular disorders. **J Mol Neurosci** 2016; 58(3): 388-393.

51. Witting N, Andersen LK, Vissing J. Axial myopathy; an overlooked feature of myopathies. **Brain** 2016; 139(Pt 1): 13-22.

52. Pareyson D, Fratta P, Pradat PF, Sorarù G, Finsterer J, Vissing J, Jokela ME, Udd B, Ludolph AC, Sagnelli A, Weydt P. Towards a European registry and biorepository for patients with spinal and bulbar muscular atrophy. **J Mol Neurosci** 2016; 58(3); 394-400.

53. Jakobsen JK, Vissing J. Neuromuskulære sygdomme. I **Medicin**. Baslund B., Feldt-Rasmussen U, Kastrup J, Sørensen PS (red). FADL's Forlag. 2. udgave. 2016: Kapitel 12, afsnit 13; 155-169.

54. Vissing J. Limb girdle muscular dystrophies: classification, clinical spectrum and emerging therapies. **Curr Opin Neurol** 2016; 29(5): 635-641.

55. Vissing J. Exercise training in metabolic myopathies. **Rev Neurol** (Paris) 2016; 172: 559-565.

56. Richard I, Laurent JP, Cirak S, Vissing J; ENMC FKRP Study Group. 216th ENMC international workshop: Clinical readiness in FKRP related myopathies January 15-17, 2016 Naarden, The Netherlands. **Neuromuscul Disord** 2016; 26(10): 717-724.

57. Marsolier J, Laforet P, Pegoraro E, Vissing J, Richard I; sarcoglycanopathies working group. 1st international workshop on clinical trial readiness for sarcoglycanopathies, 15-16 November 2016, Evry, France. **Neuromuscul Disord** 2017; 27(7): 683-692.

58. Dahlqvist JR, Vissing J. Diabetes in myotonic dystrophy. Bogtitel; Diabetes associated with single gene defects and chromosomal abnormalities. I **Frontiers in Diabetes**. Barbetti F, Ghizzoni L, Guaraldi F (Eds). 2017; 25: 182-187.

59. Ørngreen MC, Vissing J. Treatment opportunities in patients with metabolic myopathies. **Curr Treat Options Neurol** 2017 Sep 21; 19(11): 37. doi: 10.1007/s11940-017-0473-2.

60. Laforet P, Malfatti E, Vissing J. Update on new muscle glycogenoses. **Curr Opin Neurol** 2017; 30(5): 449-456.

61. van der Ploeg AT, Kruijshaar ME, Toscano A, Laforêt P, Angelini C, Lachmann RH, Pascual SI, Roberts M, Rösler K, Stulnig T, van Doorn PA, van den Bergh PYK, Vissing J, Schoser B; European Pompe consortium. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe Disease: a 10-year experience. **Eur J Neurol** 2017; 24:768–e31. doi:10.1111/ene.13285.

62. Quinlivan R, Andreu AL, Marti R; workshop participants 211th ENMC International Workshop: Development of diagnostic criteria and management strategies for McArdle Disease and related rare glycogenolytic disorders to improve standards of care 17-19th April 2015 Naarden, Netherlands. **Neuromuscul Disord** 2017; 27(12): 1143-1151.

63. Vissing J, Angelini C. Remodel mitochondria and get energized. **Neurology** 2018; 90(14): 633-634.

64. Wood L, Bassez G, van Engelen B, Lochmüller H, Schoser B; 222nd ENMC workshop participants. 222nd ENMC international workshop: Myotonic dystrophy, developing a European consortium for care and therapy, Naarden, The Netherlands, 1-2 July 2016. **Neuromuscul Disord** 2018; 28(5): 463-469.

65. Lostal W, Urtizberea JA, Richard I; calpain 3 study group. 233rd ENMC International Workshop: Clinical trial readiness for calpainopathies, Naarden, The Netherlands, 15-17 September 2017. **Neuromuscul Disord** 2018; 28(6): 540-549.

66. Straub V, Murphy A, Udd B; LGMD workshop study group. 229th ENMC international workshop: Limb girdle muscular dystrophies – nomenclature and reformed classification, Naarden, The Netherlands, 17-19 March 2017. **Neuromuscul Disord** 2018; 28(8): 702-710.

67. Jeppesen TD, Vissing J. The pathophysiology of exercise and effect of training in mitochondrial myopathies. In "**Diagnosis and Management of Mitochondrial Disorder**". Mancuso M, Klopstock T (eds). Springer, Cham Pp. 331-348; 2019.

68. Chardon JW, Díaz-Manera J, Tasca G, Bönnemann CG, Gómez-Andrés D, Heerschap A, Mercuri E, Muntoni F, Pichiecchio A, Ricci E, Walter MC, Hanna M, Jungbluth H, Morrow JM, Torrón RF, Udd B, Vissing J, Yousry T, Quijano-Roy S, Straub V, Carlier RY; MYO-MRI Working Group. MYO-MRI diagnostic protocols in genetic myopathies. **Neuromuscul Disord** 2019; 29(11): 827-841.

69. Waldemar G, Ashina M, Christensen H, Høgenhaven H, Knudsen GM, Krarup C, Paulson OB, Sørensen PS, Vissing J, Østergaard K. Neurologi. I **Medicinsk Kompendium** 19. udgave. Schaffalitzky de Muckadell OB, Haunsø S, Vilstrup H (red). Nyt Nordisk Forlag Arnold Busck, København. 2019; Kapitel:

70. Sheikh AM, Vissing J. Exercise therapy for muscle and lower motor neuron diseases. **Acta Myol** 2019; 38(4): 215-232.

71. Vissing J, Gaist D. Defekter i den neuromuskulære transmission. I **Klinisk Neurologi og Neurokirurgi**. 7. udgave. Kapitel 32. Paulson OB, Gjerris F, Sørensen PS, Waldemar G, Sørensen JCH, Sellebjerg F (red). FADL's Forlag, København. 2020: 721-721

72. Skovby F, Vissing J. Arvelige neurometaboliske sygdomme. I **Klinisk Neurologi og Neurokirurgi**. 7. udgave. Kapitel 28. Paulson OB, Gjerris F, Sørensen PS, Waldemar G, Sørensen JCH, Sellebjerg F (red). FADL's Forlag, København. 2020: 648-659.

73. Vissing J, Witting N. Muskelsygdomme. I **Klinisk Neurologi og Neurokirurgi**. 7. udgave. Kapitel 33. Paulson OB, Gjerris F, Sørensen PS, Waldemar G, Sørensen JCH, Sellebjerg F (red). FADL's Forlag, København. 2020: 722-741.

74. Andersen H, Vissing J. Neuromuskulære sygdomme. I **Medicin**. Baslund B., Feldt-Rasmussen U, Kastrup J, Sørensen PS (red). FADL's Forlag. 3. udgave. 2020: kapitel 12:13; 1054-1068.

75. International MG/COVID-19 Working Group, Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF Jr, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak RJ. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. **J Neurol Sci** 2020 May 15;412:116803. doi: 10.1016/j.jns.2020.116803. Epub 2020 Mar 25.

76. Dahlqvist JR, Widholm P, Leinhard OD, Vissing J. MRI in neuromuscular diseases: An emerging diagnostic tool and biomarker for prognosis and efficacy. **Ann Neurol** 2020; 88(4): 669-681.

77. Vissing J. Remaining diagnostic issues and start of a treatment era for muscle diseases. **Curr Opin Neurol** 2020; 33(5): 587-589.

78. Hendriksen J, Thangarajh M, Kan HE, Muntoni F. 249th ENMC workshop on: The role of brain dystrophin in muscular dystrophy: Implications for clinical care and translational research. **Neuromuscul Disord** 2020; DOI; 10.1016/j.nmd.2020.08.357

79. Almodóvar-Payá A, Villarreal-Salazar M, de Luna N, Nogales-Gadea G, Real-Martínez A, Andreu AL, Martín MA, Arenas J, Lucia A, Vissing J, Krag T, Pinós T. Preclinical research in Glycogen Storage Diseases: A comprehensive review of current animal models. **Int J Mol Sci** 2020; 21(24): E9621. doi: 10.3390/ijms21249621.

80. Laforêt P, Oldfors A, Malfatti E, Vissing J; ENMC 251st workshop study group. 251st ENMC International Workshop: Polyglucosan storage myopathies 13-15 December 2019, Hoofddorp, the Netherlands, 13-15. **Neuromuscul Disord** 2021; 31(5): 466-477.

81. Walter MC, Chiriboga C, Duong T, Goemans N, Mayhew A, Ouillade L, Oskoui M, Quinlivan R, Vázquez-Costa JF, Vissing J, Servais L. Improving care and empowering adults living with SMA: A call to action in the new treatment era. **J Neuromuscl Dis** 2021; 8(4): 543-551.

82. Dunø M, Vissing J. Myotonia Congenita. 2005 Aug 3 [Updated 2021 Feb 25]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. **GeneReviews®** [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1355/

83. Nielsen TL, Vissing J, Krag TO. Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success. Cells 2021; Mar 3;10(3):533. doi: 10.3390/cells10030533.

84. Howard JF Jr, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, Farzaneh-Far R, Murai H, Wiendl H. Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody–positive generalized myasthenia gravis. **Exp Opin Invest Drugs** 2021; 30(5): 483-493.

85. Vissing, J. “FKRP-related limb-girdle muscular dystrophy R9”. Orphanet Encyclopaedia, March, 2021, https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=34515.

86. Vissing, J. “Oculopharyngeal muscular dystrophy”. Orphanet Encyclopaedia, March, 2021, https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=270

87. Jeppesen TD, Madsen KL, Poulsen NS, Løkken N, Vissing J. Exercise testing, physical training and fatigue in patients with mitochondrial myopathy related to mtDNA mutations. **J Clin Med** 2021 Apr 20;10(8):1796. doi: 10.3390/jcm10081796.

88. Pini J, Siciliano G, Lahaut P, Braun S, Segovia-Kueny S, Kole A, Hérnando I, Selb J, Schrinzi E, Duong, T, Hogrel JY, Olmedo JJS, Vissing J, Servais L, Vincent-Genod D, Vuillerot C, Bannwarth S, Eggenspieler D, Vicart S, Diaz-Manera J; eNMD group, Lochmüller H, Sacconi S. E-Health & Innovation to overcome barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress: Nice, France, March 22-23, 2019. **J Neuromuscl Dis** 2021; 8(4): 743-754.

89. Preisler NR, Vissing J. Exercise Training and Rehabilitation Management in Pompe Disease. In **“Pompe Disease”**. Schoser B, Reuser A (eds). 3rd edition, Chapter 10, pp 154-163. UNI-MED Verlag AG, Bremen-London-Boston, 2021.

90. Lucia A, Martinuzzi A, Nogales-Gadea G, Quinlivan R, Reason S; International Association for Muscle Glycogen Storage Disease study group. Clinical practice guidelines for Glycogen Storage Disease V & VII (McArdle disease and Tarui disease) from an international study group. **Neuromuscul Disord** 2021; 31(12): 1296-1310.

91. Villarreal-Salazar M, Brull A, Nogales-Gadea G, Andreu AL, Martín MA, Arenas J, Santalla A, Lucia A, Vissing J, Krag TO, Pinós T**. Preclinical research in McArdle disease: a review of research models and therapeutic strategies. Genes (Basel)** 2021 Dec 28; 13(1): 74. doi: 10.3390/genes13010074.

92. Voermans NC, Vriens-Munoz Bravo M, Padberg GW, Laforêt P; FSHD European Trial Network workshop study group, van Alfen N, Attarian S, Badrising UA, Bugiardini P, Camano González P, Carlier RY, Desguerre I, Diaz-Manera J, Dumonceaux J, van Engelen BG, Evangelista T, Khosla S, Lópezde Munain A, van der Maarel SM, Mejat A, Monforte M, Montagnese F, Mul K, Oflazer P, Porter B, Quijano Roy S, Ricci E, Sacconi S, Sansone VA, Schoser B, Statland J, Stumpe E, Tasca G, Tawil R, Turner C, Vissing J. 1st FSHD European Trial Network workshop: Working towards trial readiness across Europe. **Neuromuscul Disord** 2021; 31(9): 907-918.

93. van den Bersselaar LR, Riazi S, Snoeck M, Jungbluth H, Voermans NC; Anaesthesia and Neuromuscular Disorders Working Group, van Alfen N, Attarian S, Badrising UA, Bugiardini E, Camano González P, Carlier RY, Desguerre I, Diaz-Manera J, Dumonceaux J, van Engelen BG, Evangelista T, Khosla S, Lópezde Munain A, van der Maarel SM, Mejat A, Monforte M, Montagnese F, Mul K, Oflazer P, Porter B, Quijano Roy S, Ricci E, Sacconi S, Sansone VA, Schoser B, Statland J, Stumpe E, Tasca G, Tawil R, Turner C, Vissing J. 259th ENMC international workshop: Anaesthesia and neuromuscular disorders 11 December, 2020 and 28-29 May, 2021. **Neuromuscul Disord** 2022; 32(1): 86-97.

Editorials and popular science papers

1. Vissing J, Schwartz M. Paternal inheritance of mitochondrial DNA. **N Engl J Med** 2002; 347: 2081-2082. (svar på letter to the Editor)

2. Vissing J. Muskelsygdomme. In: Gyldendals Leksikon, **Encyklopædien** 2003; bind 13.

3. Vissing J. Channelopathies of the nervous system. **Acta Neurol Scand** 2002; 106: 397. (Inviteret boganmeldelse)

4. Vissing J. Mitokondriesygdomme. **Læge-Helse** 2003; 1: 6-7. (oversigtsartikel)

5. Vissing, J. Mitokondriesygdomme. **Ugeskr Læger** 2003; 165: 661. (Inviteret leder)

6. Vissing J. Against a role of lactic acid on the generation of the exercise pressor reflex. **Clin Auton Res** 2003; 13: 83-84. (Inviteret leder)

7. Vissing J, Haller RG. Oral sucrose and exercise tolerance in McArdle's disease. **N Engl J Med** 2004; 350: 1575-1576. (svar på letter to the Editor)

8. Vissing J. Elektromyografi og diagnostik af muskelsygdomme. **Ugeskr Læger** 2005; 167: 3070-3071. (svar på letter to the Editor)

9. Vissing J. Lactic acid accumulation is an advantage/disadvantage during muscle activity. **J Appl Physiol** 2006; 100: 2101. (Inviteret leder)

10. Petri H, Vissing J, Witting N, Bundgaard H, Køber L. Cardiac involvement in myotonic dystrophy type 1 - do not forget the loop recorder! **Int J Cardiol** 2013; 168(2): 1541. (svar på letter to the Editor)

11. Witting N, Duno M, Vissing J. Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2. **Neuromuscul Disord** 2013; 23: 193. (svar på letter to the Editor)

12. Vissing J. Limitations of muscle biopsy in Pompe disease. **BMC Musculoskeletal Disord** 2013, 14(Suppl 2):O5.

13. Vissing J, Thage O. Neurologi i 100 år: Beretninger fra Rigshospitalets neurologiske afdeling. Paulson OB, Thage O, Waldemar G (red). 2013, s. 66-71.

14. Orngreen MC, Vissing J, Laforét P. No effect of bezafibrate in patients with CPTII and VLCAD deficiencies. **J Inherit Metab Dis** 2015; 38(2): 373-374. (svar på letter to the editor)

15. Vissing J, Duno M. Dominant LGMD2A: Alternative diagnosis or hidden digenism. **Brain** 2017; 140 (2): e8: doi: 10.1093/brain/aww283 (svar på letter to the editor)

16. Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group. Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis. **Qual Life Res** 2019; 28(8): 2255.